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EXECUTIVE SUMMARY
Towards the vision of “…a world where viral hepatitis transmission is halted and everyone living with viral 
hepatitis has access to safe, affordable and effective prevention, care and treatment services”. 
 – WHO Global Health Sector Strategy on Viral Hepatitis, 2016 
Worldwide, approximately  80  million people are living with chronic hepatitis C virus (HCV) and millions more are 
newly infected each year. Annually, 700 000 people die from HCV-related complications, including  cirrhosis and 
hepatocellular carcinoma (HCC). Despite the scope and severity of the epidemic caused by HCV, until recently, 
the global response to reduce the burden of this disease has been very limited and the available treatment was 
expensive, poorly tolerated and had low cure rates. Once infected with hepatitis C there was little chance of being 
cured, particularly for people living in low- or middle-income countries.  
The field of HCV therapeutics has evolved rapidly: in 2013, the treatment of HCV was transformed  by the introduction 
of a new class of medicines called direct-acting antivirals (DAAs). An 8–12-week course of these medicines can cure 
more than 90% of persons with chronic HCV infection. These new oral treatments offer tremendous opportunities and 
hope to all those who are infected. As with the upcoming new HIV treatment 20 years ago, we now have to ensure 
that these lifesaving treatments become accessible to all those who need them. This requires all stakeholders to work 
together to overcome barriers to access. 
This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that 
countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. 
The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can 
be overcome. It also provides information on the production of new hepatitis C drugs and generic versions worldwide, 
including where the drugs are registered, where the drugs are patented and where not, and what opportunities 
countries have under the license agreements that were signed by some companies as well as current pricing of all 
recommended DAAs, including by generic companies all over the world.  
Comparable to the early days of HIV treatment, high prices are a barrier to the scale up of HCV treatment. The new 
medicines were introduced at very high prices, in particular, in high-income countries. However, the pricing situation is not 
static and the report shows that prices in low- and certain middle-income countries are rapidly declining. Today countries 
can make lifesaving health services for the treatment of HCV a reality.  
Despite massive challenges, some pioneering low- and middle-income countries are starting to deliver hepatitis 
C treatment reaching over 1 million people in 2016.
In 2015, 275 000 people living in low- and middle-income countries had received hepatitis C treatment based on 
the new DAAs. In Egypt, with one of the world’s highest prevalence rates of hepatitis C, 170 000 people were treated 
with DAAs in 2015, and 500 000 more people received DAA treatment between January and September 2016. This 
was made possible as  the price for a 28-day supply of one of the DAAs, sofosbuvir, dropped from US$ 300 in 2014 
to US$ 51 in 2016. Other countries have increased efforts to address hepatitis C. For example, Brazil, India and 
Pakistan are expanding treatment coverage, and Georgia and Morocco have announced a plan to eliminate chronic 
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hepatitis infection. The steepest price decrease can be observed in countries with generic competition, which is 
similar to experience gained with the expansion of HIV treatment.
As treatment is scaled up, ensuring the quality of supply is of great importance. As of October 2016, the WHO 
programme prequalified the first DAA - daclatasvir from the innovator company. However, none of the generic DAAs 
that are currently on the market are approved by a stringent regulatory authority or prequalified. This is likely to 
change soon as the WHO Prequalification Programme has expanded to hepatitis, and a number of generic and 
innovator products are in the process of prequalification. This will facilitate the procurement of generic treatment by 
international programmes. 
Prices remain high in high-income countries and those middle-income countries that do not have access to generic 
formulations and who fall outside of license agreements, placing a heavy burden on health systems and leading 
to treatment rationing. For example, in upper–middle-income countries, prices vary considerably across countries 
fluctuating on negotiations with innovator companies: the price of a 28-day supply of sofosbuvir ranges from US$ 2292 
in Brazil up to US$ 16 368 in Romania. This report describes the various options these countries have to lower prices 
and make the new treatments more accessible.
Expanding HCV treatment is a critical component of a comprehensive response to hepatitis prevention and control. 
Countries also need to strengthen infection control.  The annual number of new infections in low- and middle-income 
countries is still much higher than the number of people treated and cured. A major concerted effort is needed by all 
stakeholders to turn this trend. WHO is committed to providing assistance to countries both in infection control to halt 
transmission of the virus, and to provide universal access to safe, affordable, and effective care and treatment to all 
in line with the WHO Global Health Sector Strategy on Viral Hepatitis, 2016–2021.
Methods
To obtain information for this report, WHO conducted surveys of selected countries and pharmaceutical 
companies. Representatives of ministries of health were asked to complete questionnaires regarding the 
status of registration, importation and production of generic versions of DAAs and of HCV treatment scale 
up. Countries were selected to represent a range of geographical regions, income levels and hepatitis C 
prevalence, and to present different approaches to enhancing access to affordable DAA medicines. The 
selected countries were: Argentina, Brazil, Egypt, Georgia, Indonesia, Morocco, Nigeria, Pakistan, the 
Philippines, Romania, Rwanda, Thailand and Ukraine. 
Questionnaires were also sent to four originator companies and twenty four  generic DAA-producing 
companies regarding pricing, licensing and regulatory status. Inclusion of generic suppliers did not 
imply judgement about the quality of the products. Finally, representatives of selected nongovernmental 
organizations (NGOs) were interviewed regarding their global- and country-level activities for improving 
access to DAAs. Data were collected from November 2015 to March 2016. While WHO takes full 
responsibility for the content of this report, the data on access, registration and prices have been 
reproduced as provided by countries and companies. The patent data included in this report are based 
on the WHO patent reports on daclatasvir, sofosbuvir, ledipasvir, simeprevir, ombitasvir/paritaprevir/r and 
dasabuvir, as published in June 2016. 

11. INTRODUCTION
This chapter provides an overview of the current HCV burden, the new medicines to treat and cure 
HCV, the recently adopted WHO Global Health Sector Strategy on Viral Hepatitis, 2016–2021, and a 
snapshot of national hepatitis C elimination programmes.
1.1. HCV epidemiology
Estimates of the number of people living with hepatitis C infection vary widely. This is due in part 
to the fact that some authors estimate the number of people with anti-HCV antibodies, indicating 
exposure to the virus, while others estimate the number with HCV RNA, which indicates chronic 
infection (1). In this report, the estimates of Gower et al. are used (Fig. 1.1), according to which 
there are 110 million persons with anti-HCV antibodies, indicating past or current infection, and 
80 million with HCV RNA indicating current or chronic infection (2). This corresponds to a global 
prevalence of chronic infection of 1.1%. The prevalence rates are highest (≥2.5%) in West Africa, 
Eastern Europe and Central Asia (2). Overall, approximately 70% of  persons with chronic HCV 
infection live in low- and middle-income countries (LMICs) (3). 
Key points
• Approximately 80  million persons are estimated to have chronic HCV infection, which corresponds 
to a global prevalence of 1.1%. The prevalence rates are highest (≥2.5%) in West Africa, Eastern 
Europe and Central Asia. Annually, an estimated 700 000 persons with chronic HCV infection die 
untreated.  
• Since 2014, new oral direct-acting antivirals (DAAs) have transformed HCV treatment, making 
prescribing safer and simpler. Cure rates of at least 90% have been reported after 12 weeks of 
treatment, regardless of HIV status, stage of liver disease or HCV treatment history. 
• In April 2015, WHO included a number of the new DAAs in the WHO Model List of Essential 
Medicines. 
• In April 2016, WHO issued updated HCV treatment guidelines that include recommendations on 
preferred DAA-based regimens. 
• A Global Health Sector Strategy on Viral Hepatitis for 2016–2021 was adopted in May 2016 by the 
World Health Assembly. It includes the first-ever global targets to reduce new hepatitis infections 
and deaths, with a goal of eliminating viral hepatitis as a public health threat by 2030. 
• Some countries have made significant efforts to promote universal access to new DAA medicines. 
2Hepatitis C is a small, bloodborne virus that remains infectious in dried blood for weeks (4). The 
virus spreads via injection drug use with shared, unsterilized equipment, especially when access to 
harm reduction services is limited or non-existent; from medical and dental procedures in settings 
with inadequate infection control (including dialysis centres); tattooing with reused needles, ink and 
inkwells; unscreened donor blood, blood products and organs; from mother to infant; and from 
unprotected sex, primarily among HIV-positive men who have sex with men (MSM) (5). Following 
exposure to the virus, infection becomes chronic in 60–80% of cases, while the remaining 20–40% 
of people who are infected spontaneously clear the virus (6). 
People who inject drugs (PWID) are the group with the highest HCV prevalence, an estimated 
67%. Injections among PWID with unsterilized syringes or shared injecting equipment are the 
major transmission mode in high-income countries and are increasingly being reported in LMICs 
(5, 7). The major route of transmission in LMICs is through the reuse of syringes and needles, and 
through substandard infection control practices in health-care settings. For example, in Egypt, 
an estimated 150 000 persons acquire HCV infection annually, primarily through health-care-
associated transmission (8). 
Hepatitis C can be transmitted from mother to infant, although when and how this happens is not 
well understood. The risk of mother-to-infant transmission ranges from 3% to 10% (9). This risk is 
much higher among HIV-positive mothers if they are not receiving antiretroviral therapy (ART), which 
lowers the risk of HCV and HIV transmission (9, 10). Currently, there are no interventions to prevent 
transmission from mother to infant; the safety and efficacy of DAAs have not been studied during 
pregnancy. There are no global estimates of HCV prevalence among children. HCV is thought to 
progress slowly in children, but this is not always the case, and liver damage worsens with duration 
of infection (11– 13). 
FIG. 1.1.  Global prevalence of viraemic HCV (reported and extrapolated)
Source: Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology of the hepatitis C virus infection. J Hepatol. 2014; 
61 (1 Suppl): S45–57 (2).
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3Untreated HCV can cause a range of systemic health problems outside of the liver, as well as liver 
damage (14). Once advanced liver scarring has developed, the annual incidence of cirrhosis is nearly 
10% (15). People with cirrhosis are at risk for liver failure and hepatocellular carcinoma (HCC); each 
year, these complications claim 700 000 lives (16).
1.2. New medicines: moving towards elimination
Until 2014, the standard of care to treat HCV infection was 24–48 weekly injections of 
pegylated interferon and twice-daily ribavirin tablets. This regimen was toxic, expensive, 
complicated to deliver and relatively ineffective – overall cure rates were less than 50%, 
especially for people with cirrhosis (17). Now, most people can be cured of HCV infection with 
the new DAAs; oral medicines that target different steps of the lifecycle of HCV. Numerous 
clinical trials and clinical practice have shown that DAAs are effective and better tolerated. 
Cure rates of at least 90% have been reported after 12 weeks of treatment, regardless 
of HIV status, stage of liver disease or HCV treatment history (18). This has led several 
organizations and some countries to recommend that everyone with HCV infection should 
be treated with DAAs (19). To date, eleven DAAs from four therapeutic classes – some 
formulated into fixed-dose combinations (FDCs) – have been approved by at least one 
stringent regulatory authority (see Table 1.1). In April 2016, WHO issued HCV treatment 
guidelines that included recommendations for DAA-based treatment for infection with all 
HCV genotypes (see section 2.2.3) (20).
TABLE 1.1. Recently approved oral direct-acting antivirals for the treatment of hepatitis C 
NS3/4A protease inhibitors NS5A inhibitors NS5B nucleotide 
polymerase inhibitors 
NS5B non-nucleoside 
polymerase inhibitors
asunaprevir daclatasvir* sofosbuvir (nucleotide)*
in fixed-dose combinations 
with ledipasvir or velpatasvir 
dasabuvir* 
used with ombitasvir/
paritaprevir/r
paritaprevir/r* 
fixed-dose combination with 
ombitasvir 
elbasvir
fixed-dose combination 
with grazoprevir
simeprevir ledipasvir*
fixed-dose combination 
with sofosbuvir 
grazoprevir
fixed-dose combination with 
elbasvir 
ombitasvir*
fixed-dose combination 
with paritaprevir/r
velpatasvir 
fixed-dose combination 
with sofosbuvir
r: ritonavir
* included in the WHO List of Essential Medicines; grazoprevir, elbasvir and velpatasvir were not on the market until 2016 (21)
4BOX 1.1.  Addition of DAAs to the WHO Model List of Essential Medicines 
In April 2015, the WHO Expert Committee on the Selection and Use of Essential Medicines added daclatasvir, 
sofosbuvir, ledipasvir, simeprevir and ombitasvir/paritaprevir/r + dasabuvir to the WHO Essential Medicines 
List (EML) (21). By adding these new medicines, WHO is underscoring the importance of including these 
medicines in the national formularies of countries. Essential medicines are defined as “those that satisfy 
the priority health care needs of the population”. According to the WHO Expert Committee on the Selection 
and Use of Essential Medicines, “inclusion on the EML of all DAAs proposed in the applications aims at 
promoting competition among available alternatives and allowing for the selection of optimal combination 
treatment regimens, which may or may not be existing fixed-dose combinations”. The Committee also noted 
that WHO is working to promote the rapid introduction of prequalified generic formulations and supports 
countries in accessing the new DAAs at affordable prices. The selection of medicines is based on the public 
health relevance of the disease and a comprehensive review of available evidence on the benefits and 
harms of the medicines. The WHO EML is used by governments and institutions worldwide to guide the 
development of their essential medicines lists, to make appropriate procurement decisions and to define 
health-care priorities for countries.
1.3. WHO Global Health Sector Strategy on Viral Hepatitis 
The availability of safe and highly effective treatment for HCV infection provides new 
opportunities to expand access to treatment. Lessons can be drawn from the remarkable 
success of HIV treatment scale up, whereby globally 17 million were receiving ART in 
July 2016 (22). In May 2016, the WHO World Health Assembly adopted its first-ever viral 
hepatitis strategy that is presented schematically in Fig. 1.2 (23). The strategy has an 
ultimate goal of eliminating hepatitis B and C as public health threats by 2030. Elimination 
is defined as a 90% reduction in incidence and a 65% reduction in mortality from existing 
levels. In addition to expanding prevention services, achieving these targets requires scaling 
up hepatitis treatment such that 80% of persons with chronic HBV and HCV infection are 
treated. Access to affordable and high-quality hepatitis medicines and diagnostics is a key 
element of the strategy. The strategy identifies priority actions for countries to engage in and 
for WHO to support countries in enhancing treatment and ensuring access to good-quality 
and affordable hepatitis medicines and diagnostics (see Box 1.2 and Box 1.3).
5FIG. 1.2.  Framework for the Global Health Sector Strategy on Viral Hepatitis, 2016–2021 
VISION
A world where viral hepatitis transmission is halted and everyone living 
with viral hepatitis has access to safe, affordable and effective preven-
tion, care and treatment services.
GOAL Eliminate viral hepatitis as a major public health threat by 2030.
2030 TARGETS Between 6 and 10 million infections are reduced to less than  1 million by 2030; 1.4 million deaths reduced to less than 500 000 by 2030.
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6BOX 1.2.  Priority actions for WHO (23) 
WHO is implementing priority actions for enhancing hepatitis treatment and ensuring access to good-quality 
and affordable medicines and diagnostics. 
• WHO has produced updated treatment guidelines to promote the transition to newer, more effective 
medicines that have the potential to cure most persons living with hepatitis C infection in 2016 (20) and 
new guidelines for hepatitis B and C testing will be launched in November 2016.
• WHO has also produced a Manual for the development and assessment of national viral hepatitis plans: 
a provisional document. This manual provides guidance to public health professionals tasked with 
managing a response to viral hepatitis (24). 
• WHO has expanded the WHO prequalification programme to facilitate quality assurance of new DAAs, 
and to safeguard and expand availability of quality-assured medicines and diagnostic products.
• WHO organizes an annual consultation with pharmaceutical and diagnostic companies that produce 
or have a significant development pipeline of drugs and diagnostics for hepatitis, and with partner 
organizations to advocate for adequate manufacturing capacity of producers (25). 
• WHO has assessed and published the patent situation of the new DAAs to guide Member States in their 
procurement decisions (26).
• WHO is providing Member States with technical assistance on how to expand treatment coverage. 
• WHO will annually update this report on the status of access, prices, registration of hepatitis C medicines, 
and document the situation of the response, barriers to and opportunities for countries to increase 
access to DAAs.  
BOX 1.3.  Priority actions for countries (23)  
Priority actions for countries to enhance treatment and ensure access to good-quality and affordable medicines 
• Prioritize hepatitis treatment by including access to antiviral treatment for people with chronic viral 
hepatitis B and C infection as a central component of the national hepatitis strategy and plan. 
• Establish national hepatitis treatment and care guidelines, plans and protocols based on the WHO 
hepatitis treatment and care guidelines. 
• Provide quality treatment that ensures standardized care of people with chronic hepatitis infection, 
including appropriate disease staging, timely treatment initiation, patient and drug toxicity monitoring, 
and management of liver cirrhosis, HCC and liver failure. 
• Address common comorbidities, including HIV infection and risk factors that may accelerate progression 
of liver disease, including alcohol use, and provide palliative and end-of-life care, including access to 
adequate analgesia. 
• Strengthen the national hepatitis procurement and supply management structures and processes by 
ensuring that they are integrated into the broader national procurement and supply management system. 
• Ensure the procurement of quality-assured hepatitis vaccines, medicines, diagnostics, condoms and 
other hepatitis-related commodities, including through the use of WHO prequalification. 
• Plan and implement a hepatitis medicines and commodities access strategy to reduce prices of 
hepatitis-related commodities, including, where appropriate, through implementation of flexibilities of 
the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), in accordance with the 
Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. 
• Safeguard and expand availability of WHO-prequalified generic products through the expansion of 
licence agreements and timely registration at national level.
71.4. Examples of country action towards elimination of hepatitis
The new DAAs provide the opportunity to drastically expand treatment. Some countries have 
already seized this opportunity and launched national plans with the aim of providing universal 
treatment, covering all people with chronic HCV infection. 
•	 In Australia, a civil society campaign led the government to broaden the criteria for 
eligibility for treatment. As of March 2016, the country offers universal access to HCV 
treatment to all persons with chronic HCV infection (27). Prisoners and PWID are priority 
populations for expanding coverage of treatment (28).
•	 In France, of the estimated 500 000 people living with HCV, 30 000 have been treated 
with DAAs as of May 2016. On France’s National Hepatitis Day (25 May 2016) (29), the 
Ministry of Health announced that it would provide universal access to HCV treatment 
under its national health insurance system, as of September 2016 (30). 
•	 Georgia launched a hepatitis C elimination programme in 2015. The country plans to 
expand treatment coverage from 5000 by end 2015 to 20 000 people per year (31, 32). 
•	 In Morocco, the Minister of Health has announced the goal of “Morocco without hepatitis 
C in 2030” (33).
•	 In 2015, Portugal’s Ministry of Health announced that the government would provide 
universal access to treatment – beginning with 13 000 people per year over a 2-year 
period (34). Less than a year later, 5449 people had started HCV treatment under the 
plan. Overall, 96.3% of the 1069 persons who completed treatment were cured (35). 
8This section provides an update on the number of people treated, or who were undergoing DAA-
based treatment in LMICs during 2015, and reviews some of the barriers to HCV treatment access 
that have been documented and discussed in various forums. 
2.1. Estimated number of people who received direct-acting antivirals
(DAAs)
In 2015, most of the people receiving the new DAAs were living in high-income countries. 
According to pharmaceutical company sales’ data of February 2016, 570 000 people in high-
income countries had been treated with sofosbuvir-containing regimens, which is the most 
frequently prescribed DAA (36, 37). Treatment numbers were much lower in  LMICs in 2015. 
Based on a review of  presentations at major conferences and the survey conducted by WHO for 
this report, an estimated 275 000 people in these countries received DAA-based treatment by 
the end of 2015. Of the 275 000 people treated, some 170 000 were in Egypt.  An additional 500 
000 people were reported to have started treatment in Egypt between January and September 
2016. In September 2016, additional data reported from other countries brought the overall 
estimated number of people treated with DAAs in LMICs to over 1 million (see Box 2.1). 
Expanding access to treatment in LMICs must be a high priority to meet the goals of the new 
WHO Global Health Sector Strategy on Viral Hepatitis.
2. STATUS OF THE RESPONSE
Key points
• Despite massive challenges, some pioneering low- and middle-income countries are starting to deliver 
hepatitis C treatment reaching at least 1 million people in 2016. 
• Expanding access to treatment in LMICs must be a high priority to meet the goals of the new WHO 
Global Health Sector Strategy on Viral Hepatitis.
• WHO has produced guidance to support the health sector response, increased access to new 
medicines, simplified HCV diagnosis and treatment, and optimized HCV treatment and prevention 
services, notably to reach those populations most vulnerable to and affected by HCV infection.
• Adapting health services to reach those populations and locations most affected will be key to scaling 
up HCV treatment. Decentralizing service delivery and task-shifting are approaches that could be used 
to accelerate and expand access to HCV medicines. 
92.2. The HCV treatment cascade: diagnosis and linkage to care
This section details the current barriers to HCV treatment related to diagnostics, and identifies 
possible solutions, such as dried blood spot (DBS) testing and other innovations to further simplify 
HCV testing. It reviews updated WHO treatment guidelines and outlines steps to facilitate HCV 
treatment scale up, such as task-shifting and decentralization. 
While the main focus of this report is access, it is important to bear in mind the complete 
treatment cascade as outlined in Fig. 2.1. 
BOX 2.1. WHO estimates over 1 million treated with highly effective hepatitis C medicines1 
• In Brazil, 7462 people were treated with DAAs by the end of 2015.
• In Egypt, 170 000 people were treated between October 2014 and end of 2015, and 500 000 more 
started treatment between January and September 2016.
• In Georgia, at least  5000 people were treated by the end of 2015, and 14 300 more started treatment 
between January and  September 2016 (31).
• In India, 42 000 people were treated by the end of 2015.
• In Pakistan, 47 035 people were treated from August 2014 through January 2016, and nearly 35 000 
more people have started treatment since February 2016.
• In Rwanda, 120 patients started treatment through January 2016, and the country was planning to treat 
at least 700 patients during the course of 2016.
• In Ukraine, 320 people were treated through an Alliance for Public Health programme by the end of 
2015. The programme planned to treat at least 1500 people in 2016 (38).
• In countries of the WHO Western Pacific Region, an estimated 211 100 people were treated  with DAAs 
by September 2016. These included 200 100 people in China, 5600 people in Mongolia, 4500 people 
in Viet Nam, 800 people in Cambodia and 200 people in Lao People’s Democratic Republic. 
Several other countries have introduced DAA therapy, including Argentina, Bangladesh, Côte d’Ivoire, Kenya, 
Nigeria, South Africa and Uganda.
1 Unless otherwise referenced, information on treatment numbers was obtained from country responses to the WHO country 
survey and from presentations at a “Joint European Association for the Study of the Liver/World Hepatitis Alliance Workshop 
on Regional Baseline Positions: where are we in 2016” that took place on 13 April 2016 at the International Liver Congress, 
Barcelona, Spain (webcast available at https://www.youtube.com/watch?v=MLeF_FgsxlU; accessed 5 August 2016).
FIG. 2.1.  The HCV treatment cascade
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2.2.1. HCV testing 
There are no reliable estimates of the number of people who have been tested for hepatitis, but 
it is likely that less than 5% of people in LMICs with chronic HCV infection are aware that they 
are infected (39). Lack of patient and provider awareness, poor accessibility of testing sites, 
inadequate resources for HCV testing services and commodities, and concerns about stigma and 
discrimination contribute to low diagnosis rates. In addition, HCV epidemics are heterogeneous: 
in some countries HCV prevalence is high in the general population, while in other countries HCV 
infection is concentrated in certain populations. Therefore, testing strategies must be adapted 
to the local context, with policy-makers developing testing policies and strategies that will reach 
populations with a higher prevalence (e.g. PWID) as well as those that include the majority of 
persons with hepatitis infection (e.g. general population in some countries).
Another challenge to the diagnosis of HCV infection is that it requires a two-step process. The 
first step tests for the presence of anti-HCV antibodies, and the second test, based on nucleic 
acid testing (NAT), is needed to distinguish those people who have spontaneously cleared 
the virus from those who have chronic infection. Access to NAT is limited in LMICs, as few 
laboratories have the capacity to perform these tests. These facilities are often available only 
in major cities and patients frequently bear the costs of being tested themselves. Both rapid, 
point-of-care diagnostics and decentralized, patient-focused testing services are needed 
to ensure that people are properly diagnosed and linked to care and treatment. The same 
interventions that strengthen linkage to, and retention in, HIV care and treatment may work 
for HCV. A meta-analysis of the HIV testing and care cascade in sub-Saharan Africa reported 
that the median rate of loss to follow up after an HIV diagnosis was 41% (range: 12–65%) 
(40). Point-of-care CD4 cell testing in resource-limited settings has shortened the time to 
and increased initiation of ART for people living with HIV (41, 42). Offering free HIV, HBV 
and HCV rapid testing can increase the number of people who know their HCV infection 
status. Results of rapid testing are available within minutes as compared to several days for 
laboratory-based serological testing. Where prevalence is high, testing programmes will have 
a greater yield if they focus on groups that are most affected. In a clinic in Paris for uninsured 
immigrants, testing for HIV, HBV and HCV using a combination rapid test increased uptake 
and receipt of results, from 64% to 98%, as compared with laboratory-based testing (43). 
Another opportunity to simplify diagnosis is to test for HCV core antigen, as it is a one-step 
process that is simpler to conduct and less expensive than HCV NAT (44).
There are opportunities to expand access to HCV NAT testing through scaling up HIV viral load 
testing. The same platform can be used for both HBV and HCV (45). The demand for HIV viral 
load testing in LMICs is projected to reach 15–30 million by 2018 (from 7 million in 2013).
Using DBS testing for HCV screening and diagnostic tests could increase the simplicity of 
and access to these tests. The 2016 WHO Consolidated guidelines on the use of antiretroviral 
drugs for treating and preventing HIV infection recommend DBS testing to facilitate HIV 
viral load testing in resource-limited settings (46). In high-income countries, using DBS 
has facilitated and increased uptake of HCV testing in prisons and drug treatment centres 
among people with veins that are difficult to access; it has also been effective in resource-
limited settings (47, 48). 
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2.2.2. Pre-treatment assessment: HCV genotyping
and liver disease staging
There are six major HCV genotypes. HCV genotype 1 infection is the most common; however, 
taken together, genotypes 2–6 make up more than half of all HCV infections (Fig. 2.2) (49). 
Currently, the type and duration of HCV treatment varies according to both genotype and 
cirrhosis status, as reflected in the 2016 WHO Guidelines for the screening, care and treatment 
of persons with chronic hepatitis C infection (20). Therefore, genotype testing is still necessary 
prior to treatment initiation. This test is expensive and is not widely available in LMICs because 
it requires sophisticated equipment and specially trained laboratory staff. 
Staging of liver disease to identify people with pre-cirrhosis or cirrhosis is an important pre-
treatment assessment, for two reasons: to prioritize people with advanced liver disease where 
access to HCV treatment is limited, and to determine the optimal regimen, duration and 
monitoring schedule for HCV treatment. 
Liver biopsy has been the “gold standard” for staging liver disease in high-income countries, 
although it is expensive, invasive and unpopular with patients. It is not feasible in resource-
limited settings. Recently, less invasive methods such as transient elastography and blood tests 
that measure direct markers of liver fibrosis have been used together instead of biopsy, and 
are recommended by treatment guidelines from the USA and the European Union (50, 51). In 
resource-limited settings where these less invasive methods may be unavailable or unaffordable, 
WHO recommends a combination of routine blood tests (aspartate aminotransferase-to-platelet 
ratio index [APRI] or FIB-4) to assess liver fibrosis (20). 
Source: Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus 
genotypes. Hepatology. 2015;61(1):77–87 (49). 
FIG. 2.2.  Global distribution of HCV genotypes 
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2.2.3. Treatment guidelines
Recognizing the global burden of hepatitis and the promise of DAAs, in 2014, WHO released the 
first-ever guidelines on HCV screening, care and treatment intended for LMICs. The standard 
of care for HCV is changing so rapidly that an updated version of the WHO Guidelines for the 
screening, care and treatment was issued only two years later – in April 2016. The guidelines will 
require updating with the advent of pangenotypic DAA regimens that allow a simplified public 
health approach to HCV treatment. WHO is planning to update the treatment recommendations 
in 2017.  
 For the time being, there are three WHO-recommended, preferred regimens for people without 
cirrhosis (sofosbuvir, with daclatasvir or ledipasvir or ribavirin) (Table 2.1). For people with 
cirrhosis, the same DAAs are used but the duration may differ and ribavirin may be added (20). 
The WHO guidelines also include recommendations for alternative DAA regimens (Table 2.2). 
These regimens were not considered as preferred for various reasons (for example, because 
of limited data, pill burden, adverse events, drug interactions, effectiveness limited to certain 
genotypes, safety in people with decompensated cirrhosis) (20).
None of the DAAs are approved for use among children; thus, the standard of care for hepatitis 
C infection among children remains pegylated interferon and ribavirin. Clinical trials evaluating 
the efficacy and safety of DAAs in children are under way. 
* Treatment durations are adapted from the 2015 guidelines of the American Association for the Study of Liver Diseases (AASLD) (50) and 
European Association for the Study of the Liver (EASL) (51).  
a Treatment may be shortened to 8 weeks in treatment-naive persons without cirrhosis if their baseline HCV RNA level is below 6 million 
(6.8 log) IU/mL. The duration of treatment should be shortened with caution.
b If platelet count <75 x 103/μL, then 24 weeks’ treatment with ribavirin should be given.
TABLE 2.1. Summary of recommended preferred treatment regimens with treatment durations* 
Genotype Daclatasvir/sofosbuvir Ledipasvir/sofosbuvir Sofosbuvir/ribavirin
Genotype 1 12 weeks 12 weeksa  
Genotype 2   12 weeks
Genotype 3 12 weeks  24 weeks
Genotype 4 12 weeks 12 weeks  
Genotype 5  12 weeks  
Genotype 6  12 weeks  
Genotype Daclatasvir/sofosbuvir Daclatasvir/sofosbuvir/ribavirin Ledipasvir/sofosbuvir Ledipasvir/sofosbuvir/ribavirin Sofosbuvir/ribavirin
Genotype 1 24 weeks 12 weeks 24 weeks 12 weeksb  
Genotype 2   16 weeks
Genotype 3 24 weeks  
Genotype 4 24 weeks 12 weeks 24 weeks 12 weeksb  
Genotype 5  24 weeks 12 weeksb  
Genotype 6  24 weeks 12 weeksb  
Persons without cirrhosis
Persons with cirrhosis
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TABLE 2.2. Summary of recommended alternative regimens with treatment durations* 
* Treatment durations are adapted from the 2015 AASLD and EASL guidelines (50, 51). 
a If genotype 1a-infected patient is positive for the Q80K variant, a simeprevir/sofosbuvir regimen should not be chosen.
b For genotype 1a-infected patients, treat with ombitasvir/paritaprevir/ritonavir/dasabuvir and ribavirin; for genotype 1b-infected patients, 
treat with ombitasvir/paritaprevir/ritonavir/dasabuvir.
Genotype
Simeprevir/sofosbuvir Daclatasvir/sofosbuvir Ombitasvir/paritaprevir/ritonavir/dasabuvir
Ombitasvir/paritaprevir/
ritonavir/ribavirin
Sofosbuvir/pegylated 
interferon /ribavirin
Genotype 1 12 weeksa  12 weeksb
Genotype 2  12 weeks    
Genotype 3      
Genotype 4 12 weeks   12 weeks
Genotype 5     12 weeks
Genotype 6     12 weeks
Persons without cirrhosis
* Treatment durations are adapted from the 2015 AASLD and EASL guidelines (50, 51).
a If genotype 1a-infected patient is positive for the Q80K variant, a simeprevir/sofosbuvir regimen should not be chosen.
b For genotype 1a-infected patients, treat with ombitasvir/paritaprevir/ritonavir/dasabuvir and ribavirin for 24 weeks; for genotype 
1b-infected patients, treat with ombitasvir/paritaprevir/ritonavir/dasabuvir and ribavirin for 12 weeks.
Genotype Can be prescribed 
to persons with 
compensated or 
decompensated 
cirrhosis
These regimens should be prescribed only to persons with compensated cirrhosis because they can cause 
liver failure and death when prescribed to persons with decompensated cirrhosis. Therefore, they should be 
used only in settings where specialized care is available and where the degree of cirrhosis (compensated vs 
decompensated) can accurately be assessed.
Daclatasvir/
sofosbuvir
Simeprevir/ 
sofosbuvir
Simeprevir/ 
sofosbuvir/ribavirin
Ombitasvir/
paritaprevir/
ritonavir/dasabuvir
Ombitasvir/
paritaprevir/
ritonavir/ribavirin
Sofosbuvir/
pegylated 
interferon/ribavirin
Genotype 1  24 weeksa 12 weeksa 24 weeksb
Genotype 2 12 weeks     
Genotype 3      12 weeks
Genotype 4  24 weeks 12 weeks  24 weeks  
Genotype 5      12 weeks
Genotype 6      12 weeks
Persons with cirrhosis
2.2.4. HCV treatment delivery
The safety, ease of use and high cure rates associated with DAAs allow a paradigm change from 
treating only those persons with advanced liver damage to treating all those with HCV infection. In fact, 
WHO’s Global Health Sector Strategy on Viral Hepatitis includes a target to treat 80% of all persons 
with chronic HBV and HCV infection who need treatment. For this to happen, testing and treatment 
services will need to be dramatically expanded and a number of obstacles will need to be overcome. 
Some of these apply to low-, middle- and high-income countries, such as limited awareness, low 
diagnosis rates, lack of decentralized care and treatment, stigma and discrimination, while others – 
such as high prices – affect primarily upper–middle-income and high-income countries.
Treatment services need to be planned and implemented such that equitable access to quality 
treatment services is assured for all those who need them. This is the responsibility of national 
governments, who should plan treatment services in the context of a broader national hepatitis plan 
that includes comprehensive prevention services. Such planning should be based on reliable data 
concerning the numbers and geographical distribution of people with HCV infection to help ensure 
the availability of services where they are most needed. 
Expanding access to HCV treatment will require new approaches to service delivery. To ensure 
accessibility, treatment services will need to be decentralized to lower levels of the health-care 
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system and be delivered by non-specialist providers. Task-shifting to nurses and community health 
workers has been successful for delivery of other treatments, including lifelong HIV treatment, and 
is recommended by WHO (46).  The same approach is likely to be effective for hepatitis C treatment, 
especially because of its short duration, limited monitoring requirements and safe, tolerable once-
daily regimens. Linking hepatitis treatment services with other components of the health system is 
important to help assure that these services are accessible. Opportunities for service linkage include 
locations where services are provided for reproductive and sexual health, harm reduction, drug and 
alcohol use disorders, and noncommunicable diseases.
Technology can support non-specialist care and treatment. In rural areas, telemedicine is used to 
increase the capacity to deliver HCV treatment, and there are now a range of HCV treatment smart-
phone applications to support providers and patients (52). In HIV, task-shifting and mobile or home-
based testing initiatives have improved linkage to care in LMICs, and are likely to do the same for 
HCV (53).  
Another challenge is to make treatment services accessible to specific populations with high HCV 
prevalence and variable access to health care, such as PWID, prisoners, people living with HCV/HIV 
coinfection, migrants and MSM. It is important to make special efforts so that treatment services are 
accessible to these groups. PWID, in particular, face numerous barriers to accessing HCV treatment; 
some can be surmounted by adopting enabling policies and guidelines, and decentralizing care. 
Access to harm reduction programmes and services is inadequate, and people face a range of barriers 
that complicate access to HCV treatment, including stigma and discrimination. Specific strategies to 
engage and retain PWID in HCV treatment need to be included in national treatment plans. Data 
from clinical trials and community-based programmes that deliver tailored services for PWID show 
that treatment adherence and cure rates can be high (54–56). Involving these populations in the 
development, implementation and oversight of HCV services is essential to address stigma, and 
increase access to diagnostics, care and treatment. 
2.2.5. DAA treatment in the present and the future
For now, sofosbuvir is the backbone of all multi- and pangenotypic regimens. Although data 
on sofosbuvir/daclatasvir in infection with genotypes 4, 5 and 6 are limited, this combination 
appears to be safe and highly effective for all HCV genotypes (57).
Having a single preferred first-line regimen that is effective in all genotypes (referred to as a 
pangenotypic regimen) will facilitate treatment expansion. In June 2016, a pangenotypic, fixed-
duration regimen (sofosbuvir/velpatasvir) was approved by the United States Food and Drug 
Administration (US FDA) (58). It was not included in the 2016 WHO guidelines as it had not 
been approved at the time the recommendations were formulated. Other pangenotypic FDCs 
of two or three DAA classes are in the late stages of development. Pangenotypic DAA regimens 
are optimal for resource-limited settings, as they simplify diagnosis (i.e. no need for genotyping), 
assessment of pretreatment fibrosis, procurement and delivery, and reduce prescribing and 
dispensing errors.  
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3.1. Price developments
One of the main barriers in middle- and high-income countries is the lack of funding and the high 
prices of the new medicines. Initial prices of DAAs in high-income countries were extremely high, and 
have continued to remain high in many countries. For example, sofosbuvir, which was introduced in 
late 2013, was priced at US$ 1000 per pill in the USA and sofosbuvir/ledipasvir at US$ 1125 per pill. 
This even triggered the attention of the US Congress that investigated the pricing of sofosbuvir (59). 
High prices and limited funding can force countries to ration or only gradually upscale HCV treatment. 
Some examples are given below. 
•	 In Brazil, people with no or mild fibrosis are not eligible for treatment. 
•	 Switzerland initially rationed access to treatment, excluding patients with mild or no liver 
damage because of high prices, and expanded access only after the country negotiated 
slight price reductions from originator companies (60). 
•	 In the USA, patients in California and Washington State filed lawsuits against a private 
insurance company and private payers for restricting access to HCV treatment (61, 62).
3. ACCESSING AFFORDABLE DAA 
MEDICINES IN DIFFERENT SETTINGS 
Key points
• Access to DAAs must be scaled up if treatment is to have an impact on reducing HCV mortality and 
preventing new infections.
• Increasing generic competition is beginning to have an impact on the prices of DAAs, which are 
becoming more affordable in low- and most lower–middle-income countries. Actual production costs 
are low, offering opportunities for low-cost, large-scale generic production, but high-income and upper–
middle-income countries, in particular, are facing high prices that have led to rationing of treatment. 
• Different measures have been used to increase affordability and improve access to DAAs, including 
optimized procurement, voluntary licenses, local production and patent oppositions. 
• Expanding registration of the new DAAs in LMICs is essential for expanding access.
• The WHO prequalification process can contribute to ensuring the quality of generics; WHO also has a 
surveillance and monitoring system to collect and share data on falsified medicines.
• This report provides strategic information on registration status, the patent situation and pricing to 
facilitate access to the new DAAs.
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Many middle-income countries have a high disease burden of hepatitis C. Affordable prices are a 
prerequisite for these countries to be able to increase treatment coverage. Actual production costs 
are low, offering opportunities for low-cost, large-scale generic production, as for HIV treatment. In 
January 2015, 1 kg of the active pharmaceutical ingredient (API) for sofosbuvir cost between US$ 
8000 and US$ 9000: by February 2016, the price had dropped to between US$ 1500 and US$ 
3000. It was estimated that sofosbuvir, the backbone of most HCV treatment regimens, could be 
mass-produced for just over US$ 1 per pill which could bring the cost for mass production of generic 
sofosbuvir to US$ 29 for a 28-day supply (63). With daclatasvir, the price of API has dropped from 
just under US$ 2000 per kg to approximately US$ 1500 per kg, making it possible to bring down the 
production cost to an estimated US$ 5.5 for a 28-day supply (63).
Those countries that are able to procure generic DAAs can benefit from lower prices as, with increasing 
competition, the prices of generic DAAs are dropping rapidly, as shown in Fig. 3.1 and 3.2. Generic 
production can take place in those countries where relevant patents have not been filed or granted or 
where patents are still under examination (see under section 3.5). In Egypt, where sofosbuvir is not 
patented, it is available for US$ 51 for a 28-day supply from local producers. Generic DAAs are also 
produced under license agreements (see under section 3.5.2). Prices for DAAs from these licensed 
generic producers are also falling rapidly. In January 2016, the lowest price reported for a 28-day 
supply of a generic FDC of sofosbuvir/ledipasvir by Indian licensees of the originator company for 
the local Indian market was US$ 205; by April 2016, it dropped to US$ 169 (64). The lowest price 
reported for a 28-day supply of sofosbuvir in January 2016 from a local generic producer was US$ 
15 in Pakistan (see under Chapter 5. Drug profiles). For daclatasvir, the price for a 28-day supply of 
a generic formulation dropped to US$ 120 in Morocco, US$ 61 in India and down to US$ 7 in Egypt. 
 Source: Data obtained from WHO survey on DAA pricing in selected countries, 2016 
FIG. 3.1. The price of a 28-day supply of sofosbuvir in different countries 
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3.2. Price transparency, price negotiation and price control
To enable countries to successfully negotiate more affordable prices, greater market transparency 
is needed. This report endeavours to provide comprehensive information on the current pricing 
situation, the sources from which generic products are currently available, and which countries may 
procure generic products either because they are not under patent or because they are included in the 
relevant license agreements (see for detailed information the drug profiles in Chapter 5). 
The information provided should enable countries to engage in more strategic procurement where 
legally they may procure the new DAAs from various sources, achieving better deals through 
competitive bidding processes. 
Countries that are not able to procure from generic sources have to engage in price negotiations unless 
they use TRIPS flexibilities. Successful price negotiations require market intelligence, in particular, 
on what other countries and buyers are paying. The pricing information provided in this report thus 
should assist buyers to better assess the market prices and fix goals in price negotiations. 
Many high-income countries provide for some sort of mechanism to control and fix prices in the 
medical sector. While it is beyond the scope of this report to assess the performance of the various 
systems implemented, Box 3.1 provides an overview on the current pricing levels in high-income 
countries. 
Many pharmaceutical companies have different price structures and models. Some companies 
adjust their policies on a country-by-country basis while others have predefined policies for groups of 
countries that can be based on a variety of criteria such as gross domestic product (GDP) and disease 
burden. This kind of differential pricing policy can also contribute to savings, in particular, for countries 
that are in the lowest tier. The originator company, for example, offers sofosbuvir at US$ 300/28-day 
supply and sofosbuvir/ledipasvir at US$ 400/28-day supply in the 101 countries that are included in its 
license agreement. Lessons learnt from the HIV field, however, show that while differential pricing can 
result in lower prices of medicines, generic competition is more effective in driving down prices (65). 
FIG. 3.2. The price of a 28-day supply of daclatasvir in different countries 
 Source: Data obtained from WHO survey on DAA pricing in selected countries, 2016 
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BOX 3.1.  Prices, costs and affordability of new medicines for hepatitis C treatment 
in high-income countries 
Research carried out by WHO and the Collaborating Centre for Pharmaceutical Pricing and Reimbursement 
Policies at the Austrian Public Health Institute systematically compared the price and affordability of 
sofosbuvir and ledipasvir/sofosbuvir across 26 member countries of the Organisation for Economic Co-
operation and Development (OECD) and four LMICs to assess affordability for health systems and patients. 
The total cost of treating all patients with hepatitis C, adjusted for currency differences and national wealth, 
ranged from 10.5% (the Netherlands) to 190.5% (Poland) of the current annual cost for all medicines 
among the OECD countries studied. In five OECD countries where prices are high and the burden of 
disease is high, the total cost of treating all infected patients would be more than the cost of all other 
medicines put together. If a patient had to pay for the treatment out of pocket, the total cost of a full course 
of sofosbuvir alone would be equivalent to one year or more of average earnings for individuals in 12 of the 
30 countries analysed.
The prices of the medicines for hepatitis C treatment vary considerably across countries, particularly when 
adjusted for national wealth (Fig. 3.3). Poorer countries may be paying higher adjusted prices than richer 
countries.
Paying for sofosbuvir and ledipasvir/sofosbuvir in national health systems would consume large proportions 
of their total pharmaceutical budget. The potential total cost of treatment presents a financial and ethical 
dilemma for payers and physicians. Some national health systems have therefore restricted access to 
these medicines to small groups of patients, despite the fact that almost all patients with chronic hepatitis 
C infection are likely to benefit from treatment with these medicines. For countries to increase investment 
and minimize the burden of hepatitis C, governments and industry stakeholders will need to jointly develop 
and implement fairer pricing frameworks that lead to lower and more affordable prices.
For further information on the methodology and results of the study, see reference (66).
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FIG. 3.3. Prices of medicines for hepatitis C in 30 countries 
PPP: purchasing power parity
Source: Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for 
hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016; 13(5):e1002032. doi:10.1371/journal.pmed.1002032 (66). 
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$ 39,123
$ 37,087
$ 36,039
$ 33,789
$ 31,255
$ 154,227
$ 94,500
$ 92,496
$ 90,018
$ 69,571
$ 69,056
$ 65,952
$ 63,972
$ 62,166
$ 59,789
$ 59,785
$ 57,475
$ 55,481
$ 55,107
$ 53,123
$ 53,103
$ 50,809
$ 48,165
$ 46,804
$ 43,882
$ 40,591
$ 6,012
$ 3,471
$ 2,260
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3.3. International quality assurance standards  
While price reductions offer great opportunities for scaling up treatment services, assessing the quality 
of generic medicines remains of key importance. To be eligible for international donor programmes, 
any product needs to comply with international quality assurance standards and thus needs to be 
either prequalified by WHO or authorized by a stringent regulatory authority or otherwise proven to be 
in line with international standards. As of July 2016, none of the generic DAAs produced by companies 
working within or outside the license agreements has been approved by a stringent regulatory authority 
or prequalified. However, the WHO Prequalification Programme has expanded to include the new 
DAAs, and a number of products are in the process of prequalification. In mid-October 2016, the 
Programme prequalified the first DAA – daclatasvir 30 mg and 60 mg, from the originator company. 
Several generics are in the pipeline.
The WHO Prequalification Programme was established in 2001 to assist the United Nations and 
other international procurers to identify quality-assured medicinal products for bulk purchase and 
distribution to recipient countries. It covers both finished pharmaceutical products (FPPs) and APIs. 
The prequalification requirements are similar to those of other stringent regulatory organizations 
such as the European Medicines Agency (EMA) or US FDA. This includes submission of evidence of 
safety/efficacy (for a generic, this means a bioequivalence study comparing the product against an 
acceptable comparator product, usually the innovator), as well as evidence that the API and FPP can 
be manufactured and controlled to consistently meet internationally accepted quality standards, and 
remain stable for a reasonable amount of time.
By July 2016, the Prequalification of Medicines Programme had received seven FPP applications 
for hepatitis C medicines and four sofosbuvir API applications, either to support the mentioned FPP 
dossiers, or to support prequalification of the sofosbuvir API itself. Five of the seven FPP applications are 
for sofosbuvir tablets, while the other two were for daclatasvir 30 mg and 60 mg tablets from the innovator 
company. All the FPPs and API applications have been screened and are now under full assessment.
The median time taken by WHO from submission of a dossier by a manufacturer to prequalification 
(full assessment) is approximately 200 days. Depending on a manufacturer’s experience and own 
priorities, 18 months or more may be required for a manufacturer to complete the requirements 
for prequalification, including demonstration of bioequivalence. For products already approved by a 
stringent regulatory authority, WHO prequalification can rely on such approval. In such cases, the total 
time to prequalification is generally 1–3 months.
3.4. Registration of DAAs in countries    
Registration fulfils an important public health role in assuring that a medicine is safe, efficacious 
and of good quality. Therefore, medicines cannot be sold in a given country until they have been 
approved by the relevant national or regional regulatory agency. Given that manufacturers have to 
seek authorization in all countries where they plan to market their product, they apply a step-wise 
approach, prioritizing countries using different criteria such as market size, expected revenue and 
disease burden. This means that filing for market authorization in certain countries will be delayed. 
In addition, the registration process takes time, in particular, where additional local clinical trials 
are required or authorities are understaffed. Thus, in many countries, the new DAAs are still not 
authorized for the market and consequently not available (see the data on each medicine in Chapter 
5). In some cases, the requirement for local trials was waived. For example, in India, community-
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based advocates successfully petitioned – along with generics companies – to obtain waivers for 
sofosbuvir and daclatasvir (67, 68). As a result, these DAAs were registered and became available 
much sooner than if in-country clinical trials needed to be conducted. 
The lack of registration of the originator products also hampers the availability of generic alternatives, 
including in those countries that have voluntary license agreements. In general, when an originator 
company registers its product, this facilitates the registration of generic versions, as regulatory 
authorities and generics producers can refer to the dossier and market authorization held by the 
originator (unless data exclusivity rules prevent generic manufacturers from referring to the data 
submitted by the originator company). It is also important that the originator companies register not 
only their FDCs, but also the individual components to allow new generic combinations, for example, 
of sofosbuvir and daclatasvir, to enter the market (57, 69, 70). 
In the absence of registration of the originator products, countries can rely on prequalification and 
referral to other stringent regulatory approvals to speed up registration of generic DAAs. The fact that 
the license agreement on daclatasvir requires the generic manufacturers to seek prequalification or 
approval by a stringent regulatory authority should facilitate their registration and uptake. 
BOX 3.2.  Falsified hepatitis C products in South-East Asia 
WHO has developed a surveillance and monitoring system designed to significantly improve the 
quantity and quality of data on substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) 
medical products. As of March 2016, over 1050 products had been reported to the WHO database. 
(See http://www.who.int/medicines/publications/drugalerts/en/.)
In February 2016, WHO was informed by a local nongovernmental organization (NGO) working in Myanmar 
about falsified versions of two of the new DAAs included in the WHO EML. It is almost impossible, even 
for a trained health-care practitioner, to identify these products as false based solely on visual inspection. 
The manufacturer indicated on the label confirmed to WHO that it does not manufacture these products, 
which have therefore been confirmed to be false. WHO issued an international drug alert about these 
products and called for detailed laboratory analysis to better assess the risk to public health. Samples are 
still pending laboratory testing. These products are thought to still be in circulation. 
3.5. Overcoming patent-related barriers to access
A patent allows the patent holder to prohibit others from commercially using the invention and, for 
example, to manufacture, sell, export or import the patented product. Thus, whether a country can 
procure generic medicines depends on whether patents are filed and granted or not and, if patents are 
filed or granted, whether the country in question is included in the territory of the respective voluntary 
license agreements. A country can also issue a compulsory license to access generic treatment.  
Numerous patents have been filed in relation to the new DAAs. It is important for procurement 
agencies to be aware of the patent situation in their country when they engage in procurement or 
negotiate pricing agreements. WHO has published patent reports on daclatasvir, sofosbuvir, ledipasvir, 
simeprevir, ombitasvir/paritaprevir/r and dasabuvir, and updates them regularly (26). These reports 
provide an indication of what kind of patents have been filed on the different medicines, to what extent 
they are relevant and where these patents have been filed. See the summary in Table 3.1. UNITAID 
has published additional reports covering elbasvir, grazoprevir and velpatasvir in July 2015 (71–73).
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Patents can be granted for products and manufacturing processes if all of the patentability criteria 
are met. In the case of chemical molecules, often a number of patents are filed reflecting different 
steps in the drug development and manufacturing process. Product patents in the area of medicines 
usually cover the chemical molecule or active ingredient (referred to as primary patents) and, where 
considered patentable, variations of an existing chemical molecule, combinations, manufacturing 
processes, methods of treatment and formulations (referred to as secondary patents). For more 
information, see the WHO Patent reports (26).
Patents are territorial rights and thus are valid only for the country or region where they are applied for 
and granted. The patent applicant may decide to apply for and pursue patent protection in one country 
but not in another. For example, the primary patents for sofosbuvir were not filed in Morocco and 
Georgia. Definition of patentability criteria and the practice of patent offices can vary from country to 
country. Some countries (including Argentina, India and the Philippines) interpret patentability criteria 
more narrowly than others or have excluded certain pharmaceutical inventions from patentability. Thus, 
the same patent application may be granted in one country and rejected in another (74–76).
3.5.1. Patent oppositions
With respect to the new DAAs, a number of NGOs as well as generic companies have filed patent 
oppositions in different jurisdictions. Many patent laws allow interested third parties to file such 
oppositions against a patent before and/or after it has been granted (pre- or post-grant opposition). 
Such procedures help ensure that only those patents that meet all patentability criteria are granted and 
upheld. Based on the oppositions filed and as a result of the patent examination process, a number of 
patent applications for DAAs have been refused in different countries. For details, see http://www.who.
int/phi/implementation/ip_trade/ip_patent_landscapes/en/ (26). 
3.5.2. Voluntary license agreements
Many LMICs can procure generic daclatasvir, sofosbuvir and ledipasvir from manufacturers that have 
entered into a license agreement with the originator companies. Under such license agreements, a 
patent holder permits a generic company to manufacture and sell the patented medicine in a defined 
number of countries. In return, the patent holder may receive royalty payments. The originator company 
of sofosbuvir has signed license agreements with 11 Indian generic manufacturers, allowing them to 
sell and market sofosbuvir, ledipasvir and velpatasvir in 101 countries (77). The originator company of 
daclatasvir has signed an agreement with the Medicines Patent Pool, which enables sublicensing to 
multiple generic manufacturers and marketing in 112 countries (78). All countries included in these 
agreements (see Table 3.2) can procure generic products from the licensees. As the Indian companies 
that are generic licensees for sofosbuvir have started to manufacture and sell sofosbuvir, prices have 
fallen considerably (see Chapter 5. Drug profiles). To allow a competitive market, license agreements 
need to cover a broad territory, be non-exclusive, and include a number of generics-producing 
companies. They should be made public and ideally be negotiated through the Medicines Patent Pool 
to ensure transparency, and include pro-competitive, public health-friendly terms and conditions.
Both licenses allow for the marketing of generic formulations of DAAs for a large number of countries 
(including more than two thirds of all middle-income countries for daclatasvir). However, these 
agreements do not include a number of middle-income countries with large populations and disease 
burden, notably Thailand (0.9 million), Brazil (1.9 million) and China, the latter having the largest 
number of people living with HCV infection (8.9 million) (2) (and see Chapter 5. Drug profiles). 
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TABLE 3.1. Summary of patent information of selected direct-acting antivirals in certain low- and middle-income countries
G, patent(s) granted; F, patent(s) filed/pending; --, not filed/no patent application; •, data not available; *, patent rejected; 
 = Included in voluntary license agreements with Gilead (sofosbuvir+ledipasvir) and Bristol-Myers Squibb (daclatasvir). For sofosbuvir and ledipasvir of the EAPO 
countries, included are Kyrgyz Republic, Tajikistan and Turkmenistan and for declatasvir, included are Azerbaijan and Turkmenistan.  
ARIPO, African Regional Intellectual Property Organization; GCC, Cooperation Council for the Arab States of the Gulf; EAPO, Eurasian Patent Organization; EPO, The 
European Patent Office; OAPI, Organisation Africaine de la Propriété Intellectuelle (African Intellectual Property Organization) 
Notes: For each molecule, the first letter relates to the primary patent; the second letter combines information for all other secondary identified patents (except for 
sofosbuvir that has two primary patents)
For more comprehensive data on the patents and license agreements, please see the WHO Reports on the patent situation of key products for treatment of hepatitis 
C, updated June 2016: http://www.who.int/phi/implementation/ip_trade/ip_patent_landscapes/en/ (26).
simeprevir sofosbuvir ledipasvir daclatasvir paritaprevir ombitasvir dasabuvir
Argentina G G F F F G F F F F F F G G
ARIPO G F -- G F F -- -- • • • • • •
Australia G G G G G F G G G G G G G G
Brazil F F F F F F F F F • • F • •
Chile F G G F F F G G • F F F F F
China G G G F* G F G G G G G G G F
Colombia G G G G* G G G G G F F G F F
Costa Rica F F* -- F -- F -- -- F • • F F F
EAPO G G -- F G F G G G F G F • F
EPO G G G G G F G G G G G G G F
Ecuador F F -- F F F -- -- F F F F F F
Egypt F F -- F* -- F F* F • • F F F F
Ethiopia -- -- -- -- -- -- -- -- • • • • • •
GCC F F -- F -- F F G • • F F F •
Georgia -- -- -- -- -- -- -- -- • • • • • •
Indonesia F -- G F F F -- F • F • F F F
India F G G F F F F F F F F F F F
Iran (Islamic Republic of) -- -- -- -- -- -- -- -- • • • • • •
Israel G G G G G F G G G F G F F F
Japan G G G  G G G G G G G G G G G
Jordan F F -- -- -- -- -- -- • • • • • •
Lebanon • • • • • • G -- • • • • • •
Malaysia G F G F -- F -- F F F F F F F
Mexico G G G G G F G G G F F G F F
Morocco -- -- -- G -- F -- -- • • • • • •
New Zealand G G G G G G G G G G G G G G
Nigeria G -- -- -- -- -- -- -- • • • • • •
OAPI G -- --  G G F -- -- • • • • • •
Pakistan F F -- F F F -- -- • • • F F •
Peru G -- -- F G F G G G F F F F F
Philippines G G G F -- F -- F • G G G F F
Russia G G G G -- F G G -- G • • G •
South Africa G G G G G F G G G G G G G G
Republic of  Korea G G G G G F G G G G F G G F
Singapore G G G G G F G G G G F F G G
Thailand F F F F F F F F -- F • F F •
Tunisia -- -- -- -- -- -- -- -- • • • • • •
Ukraine G G -- F G F -- -- G • G G • F
Uruguay F -- -- F F F -- F -- F F F F F
USA G G G G G G G G G G F G G G
Venezuela • • • • • • F F • • • • • •
Viet Nam -- F -- F F F -- -- -- • F F F F
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BOX 3.3.  Voluntary license agreements for hepatitis C medicines 
In 2014, the originator company of sofosbuvir granted non-exclusive licenses initially to seven Indian 
companies to produce generic versions of sofosbuvir and ledipasvir/sofosbuvir for use in 91 countries 
and later expanded to 11 Indian companies and 101 countries, and included the single-tablet regimen of 
sofosbuvir/velpatasvir. The agreements permit the licensees to manufacture and sell sofosbuvir, ledipasvir 
and velpatasvir in the licensing territory and thus enable 101 countries to procure generic products. This 
includes 31 low-income countries, two high-income countries (Equatorial Guinea and Seychelles), and 68 
middle-income countries (79).
The license agreement allows licensees to combine the licensed products with other DAAs owned by 
different producers, for example, daclatasvir, which enables the development of alternative generic 
combinations. The agreement also allows the licensees to sell products to countries that have issued a 
compulsory license for importation. The license agreement, in practice, does not allow the shipping of 
products to countries where any patent related to the respective DAA has been filed or granted. Licensees 
are obliged to procure their API only from licensed Indian API manufacturers, which limits the competition 
in the API market. The license requires the licensees to implement anti-diversion measures (see Box 4.1). 
It does not require the licensees to seek WHO prequalification (77).
The originator company of daclatasvir signed a license agreement for daclatasvir with the Medicines Patent 
Pool in 2015, which had expanded its mandate to cover HCV and tuberculosis drugs in addition to those for 
HIV. By July 2016, the Medicines Patent Pool granted sublicenses to seven Indian generic manufacturers 
to produce daclatasvir for 112 LMICs, representing 69% of the burden of HCV in LMICs. This royalty-free 
license allows sub-licensees to combine daclatasvir with other medicines and to develop new generic 
FDCs. Contrary to the sofosbuvir license, the licensees are allowed to sell daclatasvir in countries not 
included in the licensing agreement if a patent has not been filed or granted, as long as they do not rely on 
the technology of the innovator company and use an alternative production process. This further expands 
the number of countries that can procure generic daclatasvir (78).
Similar to the sofosbuvir agreement, licensees can sell products to countries that issue a compulsory 
license. The license requires the generic manufacturers to seek WHO prequalification or approval by 
a stringent regulatory authority. These license agreements include technology transfer and waive data 
exclusivity to facilitate the registration of generic products in the territory.
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Sources: Gilead: access partnerships [website] (http://www.gilead.com/responsibility/developing-world-access/access%20partnerships, accessed 8 
September 2016); and The Medicines Patent Pool signs first sub-licenses for hepatitis C medicine daclatasvir. In: Medicines Patent Pool [website]. 
Geneva: Medicines Patent Pool; 2015 (http://www.medicinespatentpool.org/the-medicines-patent-pool-signs-first-sub-licences-for-hepatitis-c-
medicine-daclatasvir/, accessed 30 June 2016) (77, 78).
 
TABLE 3.2. List of countries included in voluntary licenses for sofobuvir and/or daclatasvir (as of June 2016)
African Region Eastern Mediterranean Region South-East Asia Region
Algeria Afghanistan Bangladesh
Angola Egypt India
Benin Iraq Bhutan
Botswana Morocco Democratic People’s Republic of Korea
Burkina Faso Occupied Palestine Territory Indonesia
Burundi Pakistan Myanmar
Cameroon Syrian Arab Republic Nepal
Cabo Verde Tunisia Sri Lanka
Central African Republic Yemen Timor-Leste
Chad
Comoros
Congo
Côte d’Ivoire European Region Western Pacific Region
Democratic Republic of Congo Azerbaijan Cambodia
Djibouti Georgia Cook Islands
Equatorial Guinea Kyrgyzstan Lao People’s Democratic Republic
Eritrea Turkmenistan Fiji
Ethiopia Uzbekistan Kiribati
Gabon Marshall Islands
Gambia Region of the Americas Micronesia
Ghana Antigua and Barbuda Mongolia
Guinea Belize Nauru
Guinea-Bissau Bolivia Niue
Kenya Costa Rica Palau
Lesotho Cuba Papua New Guinea
Liberia Dominica Philippines
Libya Dominican Republic Samoa
Malawi Ecuador Solomon Islands
Maldives El Salvador Tuvalu
Mali Grenada Vanuatu
Madagascar Guatemala Viet Nam
Mauritania Guyana
Mauritius Haiti
Mozambique Honduras
Namibia Jamaica
Niger Nicaragua
Nigeria Panama
Rwanda Paraguay
Sao Tome and Principe St Lucia
Senegal St Vincent and the Grenadines
Seychelles Suriname
Sierra Leone
Somalia
South Africa
South Sudan
Sudan
Swaziland
Togo
Tonga
Uganda
United Republic of Tanzania
Zambia
Zimbabwe
Included in licensing agreement
Not included in licensing agreement
Voluntary license
daclatasvir sofosbuvir 
Voluntary license
daclatasvir sofosbuvir 
Voluntary license
daclatasvir sofosbuvir 
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3.5.3 Compulsory licensing 
While countries included in the voluntary license agreements benefit from lower prices through 
generic competition, countries outside the territory where patents have been filed and granted may 
have to use other means to ensure affordable prices. Such measures can include price regulation, 
price negotiations, including under differential pricing schemes, as well as the use of the flexibilities 
of the TRIPS Agreement, which include compulsory licensing.
Contrary to a voluntary license, a compulsory license can be issued by a government to allow a 
local company to manufacture the patented product or to import it under certain conditions. The 
TRIPS Agreement contains certain conditions (Article 31) (74). The procedure to grant a compulsory 
license is, however, governed by the respective national (patent) law, which has to define the specific 
grounds for which a compulsory license can be granted as well as the procedure to be followed.
Under a compulsory licence, countries can choose whether they want to import or locally produce 
the medicine. Unlike voluntary licenses, compulsory licenses are in principle limited mainly to the 
country that issued the license as they have to serve “predominantly for the supply of the domestic 
market” (Article 31 of the TRIPS Agreement). However, a mechanism put in place in 2003 allows 
World Trade Organization (WTO) Members to waive this condition to grant special compulsory 
licenses for the manufacture and export of generic medicines to countries that do not have local 
manufacturing capacities in order to supply the needed medicines to their patients (see http://www.
who.int/phi/promoting_access_medical_innovation/en/ (74)). The system also includes provisions 
that can support the production or importation of medicines at the regional level. So far, no country 
has used compulsory licensing for any DAA. 
It was reported in the media that Romania considered the use of this instrument to import generic DAAs 
(80). Obtaining a market authorization for a generic import, however, would have been problematic. To 
legally import and distribute a medicine in Europe, the medicine needs to be authorized by the EMA for 
the European market to guarantee its quality, safety and efficacy, or by a national authority. European 
legislation prevents generic applicants, for at least eight years, from relying on the clinical trial data of the 
originator company to document the safety and efficacy of their product. This prevents the registration 
of generic sofosbuvir, for example, even in the absence of a patent or a compulsory license. Thus, 
unless the generic applicant reproduces its own data by conducting new clinical trials, which would be 
very costly and time-consuming (and raise ethical concerns), it will not be able to enter the market in the 
absence of a marketing authorization even if a compulsory license is granted, unless this compulsory 
license also waives the data exclusivity. Furthermore, experiences from middle-income countries that 
have used standard compulsory licenses show that they are likely to face political pressure by other 
countries as well as the pharmaceutical industry and its lobby groups.
As outlined in the Global strategy and plan of action on public health, innovation and intellectual 
property, WHO provides, upon request, in collaboration with other competent organizations, technical 
support to countries that intend to make use of the flexibilities contained in the TRIPS Agreement 
as recognized by the Doha Declaration on the TRIPS agreement and public health (81). Further 
information can be found in the WHO Guide for the application and granting of compulsory licences 
and authorization of government use of pharmaceutical patents (82). 
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3.6. Procurement
Sound procurement mechanisms are a prerequisite to ensure the availability and affordability 
of essential medicines in general. While it is beyond the scope of this report to describe the 
characteristics and principles of a good pharmaceutical procurement scheme, pooling 
procurement is one option that is highlighted. Pooled procurement, whereby several countries 
negotiate prices as one entity, can be more efficient and allows countries to get volume-based 
discounts. Regional negotiations can improve procurement, as the example of Organisation of 
Eastern Caribbean States (OECS)/Pharmaceutical Procurement Service or the Gulf Cooperation 
Council (GCC) Procurement System has shown. Brazil, along with a number of other Latin 
American countries, has jointly negotiated a price of US$ 2292 for a 28-day supply, for the 
procurement of sofosbuvir from the originator company (83).
Well-planned procurement and efficient pharmaceutical production is aided by reliable information 
on the projected treatment needs. For HIV, demand forecasting is an essential tool to ensure 
regular supply. This demand forecasting is challenging for hepatitis because of the uncertainty 
in the numbers of people with HCV infection and varying treatment eligibility criteria in different 
countries. The lack of international funding or procurement mechanisms also leads to a more 
scattered market than for HIV, which further complicates reliable demand forecasting. 
28
4. OVERCOMING ACCESS BARRIERS: 
EXAMPLES FROM SELECTED 
COUNTRIES2 
4.1. Approaches in different countries
The following section presents examples of certain countries that have made HCV treatment more 
widely available for their populations. The different country responses highlight how countries that 
were able to obtain affordable prices for DAAs were able to commit to treatment scale up and 
implement national treatment programmes (e.g. Egypt). Some countries have negotiated with 
originator companies, but even so, prices remain high, leading to treatment prioritization or rationing 
(e.g. Argentina, Brazil, Romania). Civil society groups in some middle-income countries have filed 
patent oppositions (e.g. Argentina, Brazil, Thailand and Ukraine). In some countries where the patent 
situation allows for it, local production of generics has resulted in lower prices (e.g. Argentina, Egypt, 
Morocco and Pakistan). Some countries are relying on donations or programmes run by NGOs to 
start providing treatment (e.g. Georgia, Ukraine). Rwanda is an example of a low-income country that 
is developing a national treatment programme.  Table 4.1 presents a summary of findings of the WHO 
survey conducted in 13 countries on improving access to DAA medicines.  
2 Unless otherwise noted, the information in this chapter comes from the WHO survey on access to DAAs in selected 
countries.
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BOX 4.1.  Egypt’s response to hepatitis C 
The prevalence of HCV in Egypt is among the highest in the world (7% among 18–59 years age group) 
(84). Initially, the virus was spread through reuse of syringes in a national anti-schistosomiasis campaign. 
Now, unsafe medical injections, inadequate infection control and intrafamilial transmission are driving 
transmission, which was estimated at 150 000 new cases each year (8, 84–88). Thus, improving infection 
control remains a major challenge and a prerequisite for controlling the spread of the virus. Egypt has 
treated more people than any other low- or middle-income country. In 2015, approximately 170 000 
people were treated with DAAs in the public sector. In 2016, 500 000 more people started DAA-based 
treatment between January and September 2016.
The groundwork for Egypt’s response to HCV was undertaken a decade ago, when Egypt’s Ministry of 
Health (MoH) established a National Committee for Control of Viral Hepatitis. In 2012, the MoH and 
the National Committee worked with partners to create Egypt’s Plan of Action for the Prevention, Care 
and Treatment of Viral Hepatitis, 2014–2018, which was updated to include DAAs in 2014. Over 90% 
of Egyptians with hepatitis C are infected with genotype 4, which simplifies treatment selection and 
procurement (89). Egypt’s Plan of Action addresses pricing and affordability, procurement processes, 
surveillance, infection control, blood safety, prevention via vaccination for hepatitis B, care and treatment, 
provider and community education, and a research agenda (90).  
Egypt entered into price negotiations for DAAs soon after these medicines were introduced to the market 
and became the first country to negotiate a large reduction in the price of sofosbuvir with the originator 
company. At US$ 300 for a 28-day supply, it was at the time the lowest price in any country (91). As one 
patent on sofosbuvir was rejected in the examination process and other relevant patents on sofosbuvir 
were not filed or granted, the treatment programme has been able to diversify procurement to include local 
companies, which has lowered the price for a 28-day supply to US$ 51. 
Daclatasvir is available from the originator company at US$ 167 for a 28-day supply. Local production of 
daclatasvir by generic producers has reduced prices down to US$ 7 for a 28-day supply in the public sector, 
the lowest price in the world. Assuring the quality of locally produced DAAs remains key to ensuring the 
success of the treatment programme and preventing the development of drug resistance (see section 3.3). 
Several factors have made Egypt’s HCV Programme a success:
• high level of commitment from the president and government; 
• high level of awareness among the population;
• an established National Committee to develop and implement plans and programmes;
• a national network of treatment centres;
• effective price negotiations with originator companies for pegylated interferon and DAAs soon after 
they came on the market;
• local production of affordable generic and biosimilar HCV medicines;
• predominance of a single genotype, which facilitates the selection of treatment regimens;
• a patient online treatment registration system.
During the past two years since introduction of the DAAs to the hepatitis treatment protocol in Egypt, 
the Egyptian Government spent around 2.8 billion L.E. (US$ 350 million) for the HCV national treatment 
programme. Almost 88% of treated patients were sponsored by the government whereas 12% of patients 
paid out of pocket. Egyptians pay up to six times more for their HCV treatment in the private market (90). 
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4.2. Generic competition and local production
Generic competition is the most effective way to drive down prices for medicines. In the case of HIV 
treatment, generic competition, streamlined procurement mechanisms and economies of scale have 
reduced the price of a first-line antiretroviral regimen by 99%, from US$ 10 000 per person per year 
to US$ 100 per person per year (92). 
Argentina is a high-income country, and therefore not included in voluntary licensing agreements. 
Sofosbuvir is registered by the originator company in Argentina but is not under patent as the 
applications are under review. This has allowed a local company to produce generic sofosbuvir (93). 
In Argentina, the price per patient-month for sofosbuvir from the local generic producer is US$ 501 
(versus US$ 2086 for sofosbuvir from the originator company). However, costs of the generic product 
are still high as compared with other countries and suppliers. Whether local production can continue 
in the long run depends on the outcome of the patent examination procedure.
Although Argentina is currently limiting treatment to a total of 1200 people with cirrhosis, a second 
phase is planned, which will provide treatment to persons without cirrhosis, people with HIV/HCV 
coinfection and those with serious extrahepatic manifestations. A strong civil society movement is 
pushing for increased access to DAAs. Fundación Grupo Efecto Positivo, the Argentinian Network of 
Positive People (Redar Positiva) and Initiative for Medicines, Access & Knowledge (I-MAK) have filed 
a patent opposition against sofosbuvir. 
Morocco established its national HCV programme in 2012; it provides HCV diagnostics, genotyping 
and liver disease staging, and has treated over 1700 people with pegylated interferon and ribavirin. 
The country is currently developing a national strategy and updating its treatment guidelines. The 
primary patents for sofosbuvir, ledipasvir and daclatasvir were not filed in Morocco, allowing for local 
production and importation of generic products. While Morocco was not included in the initial license 
agreement on sofosbuvir, ledipasvir and velpatasvir, it was added when the geographical scope was 
expanded. Morocco is also included in the voluntary licensing agreement for daclatasvir and can thus 
procure the API for these DAAs from licensed suppliers as well. The Minister of Health of Morocco 
has announced the goal of “Morocco without hepatitis C in 2030” (33). Morocco also benefits from a 
strong civil society movement, including the International Treatment Preparedness Coalition-Middle 
East North Africa (ITPC-MENA) and The Association against AIDS (ALCS), the “Collectif pour le droit 
à la santé Maroc” that lobby for increased access.
Pakistan has one of the world’s highest HCV prevalence rates. Over 257 000 people have been 
treated with interferon and ribavirin. The MoH is updating the country’s HCV treatment guidelines 
to include DAAs and planning to distribute sofosbuvir via public sector programmes. In Pakistan, 
the primary patents on sofosbuvir have not been filed. Some secondary patents are pending. Local 
companies have used this situation to enter the market with generic products. Pakistan is included 
in the voluntary licencing territories for sofosbuvir and daclatasvir, and can thus also procure 
generic products from the respective licensees. Sofosbuvir has been registered, and registration 
of daclatasvir is pending. Sofosbuvir is already available through the private sector, sold by local 
and foreign companies that signed the license agreements. In the private sector, 47 035 people 
were treated with a sofosbuvir-based regimen from August 2014 through January 2016, and nearly 
37 000 people have started treatment since February 2016. Generic competition has resulted in 
prices of US$ 15 for a 28-day supply of sofosbuvir from a local generic producer, the lowest price in 
the world (see section 3.1 and Chapter 5. Drug profiles). 
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4.3. Civil society advocacy fuels negotiations
In Thailand, civil society groups have been lobbying for access to hepatitis C medicines for nearly a 
decade. Thai civil society has protested against the high DAA prices and filed a patent opposition 
against one patent application for sofosbuvir (94). Thailand is not included in the voluntary licensing 
agreements. The primary patent for daclatasvir is under examination. Thailand has a national 
programme for HCV, under the National Health Security Office (NHSO). The NHSO is the public body 
in charge of implementing universal health coverage established by Thai Law. Treatment supported 
by the NHSO consists of pegylated interferon and ribavirin. The NHSO also offers financial support of 
up to US$ 300 per patient for the costs of laboratory tests. The Thai government is engaging in price 
negotiations with originator companies to introduce DAAs in the public sector. 
4.4. Political will
Strong political will and civil society engagement in Brazil led the country to provide free HIV treatment. 
In 2002, the country established a national hepatitis programme. In 2011, the MoH distributed 
rapid HCV test kits to its counselling and testing centres, expanded its laboratory network, and set 
up a referral system for people who were diagnosed with hepatitis C. Brazil is not included in the 
voluntary licensing agreements. Brazil concluded pricing negotiations with originator companies and 
later engaged in joined negotiations with the Mercosur countries and their Associated States (83).  
Brazil updated the national treatment guidelines in 2015 to include DAAs. Brazil provides HCV 
treatment at no charge for eligible patients. Now, sofosbuvir, daclatasvir and simeprevir are available 
at national, provincial and district hospitals, at district clinics and some pharmacies, although access 
is currently limited to people with moderate-to-serious liver damage (METAVIR score ≥F2).  
4.5. Efficient regulatory processes for rapid scale up
Rwanda is the only low-income country to have registered sofosbuvir, daclatasvir and sofosbuvir/
ledipasvir at the time the survey was conducted. Although the country faces many challenges (lack of 
awareness, limited access to diagnostics and treatment, need for provider education), rapid progress 
has been made. A national hepatitis programme was established in 2011. Rwanda began working on 
HCV in 2015 and has already issued DAA-inclusive treatment guidelines. Rapid HCV tests are being 
validated, training for doctors and nurses at provincial and referral hospitals is under way, and will 
be expanded to include pharmacists, laboratory technicians, nutritionists and counsellors to facilitate 
decentralization of care.  
Rwanda is included in the voluntary licensing agreements and can procure a 28-day supply of 
sofosbuvir/ledipasvir from the originator company at US$ 400 under the differential pricing policy of 
the company. Rwanda’s public and private insurers cover 85–90% of treatment costs for 20% of the 
population. The remaining 80% of the population depends on community-based health insurance, 
which is considering provision of HCV treatment. 
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4.6. Starting out
In January 2016, the Philippines MoH convened a Technical Working Group on Viral Hepatitis. At 
the same time, the MoH met with doctors and patients about HCV treatment needs, and held pricing 
negotiations with companies. 
The country is included in the licensing agreements for sofosbuvir, sofosbuvir/ledipasvir, 
sofosbuvir/velpatasvir and daclatasvir, and thus can procure generic products from the licensees. 
While patents for sofosbuvir have been filed and one granted, the patent situation for daclatasvir 
is likely to allow for import or local production independent of the license agreement (see Table 
3.1, Table 3.2 and http://www.who.int/phi/implementation/ip_trade/ip_patent_landscapes/en/ 
(26)). Registration for these DAAs is either planned or under way. Sofosbuvir was registered by 
the originator company in mid-2015, and registration for sofosbuvir/ledipasvir was filed in 2015. 
Once these DAAs become available, the country will need political will, a national plan, treatment 
guidelines, a budget for providing treatment to people living with HCV infection and training for 
health-care providers.  
4.7. Building on a national plan and adopting treatment guidelines
Treatment guidelines provide a framework for standardized treatment and quality care, and facilitate 
reimbursement. Although DAAs have made HCV treatment much simpler, health-care providers will 
still need guidance on how to diagnose, stage and cure people with HCV. 
Georgia’s small size and population, high HCV prevalence (~6%) and strong civil society advocacy 
led the country to take a bold step: develop a national hepatitis C elimination plan. To assist in 
the planning and implementation, the government sought technical assistance from WHO, the 
US Centers for Disease Control and Prevention (CDC), and international clinical experts. Technical 
assistance was provided to the MoH to conduct a national population-based HCV survey, which gave 
a better picture of the prevalence and distribution of HCV infections in the country (32).
Since 2011, Georgia had been providing pegylated interferon and ribavirin to people with HIV/
HCV coinfection, with support from the Global Fund to Fight AIDS, Tuberculosis and Malaria 
(Global Fund). The treatment programme was expanded to cover prisoners and then the general 
population. Once DAAs came on the market, Georgia began discussions with  an innovator 
company about becoming a test case for HCV elimination. It prepared a comprehensive national 
programme, including prevention, surveillance and data management systems, assessment of 
laboratory capacity and drug procurement, and training. Georgia’s HCV elimination programme 
was launched in 2015. Initially, it focused on subsidizing HCV diagnostics and treating 5000 people 
with severe liver disease, using pegylated interferon, ribavirin and sofosbuvir under a donation 
programme with the originator company (32).  
Georgia plans to expand treatment coverage to 20 000 people per year, using a sofosbuvir-based regimen 
under the donation programme. The Georgia programme includes strict anti-diversion measures that 
may compromise adherence and treatment outcomes. These include requiring proof of identity and 
citizenship, photographing people taking their first dose of medication and dispensing only a month’s 
supply of medicine at a time, contingent on the return of empty pill bottles or viral load testing.  It is 
important that anti-diversion measures do not impede access or lead to discrimination (see Box 4.2).
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BOX 4.2.  Anti-diversion measures 
The existing large price discrepancies and lack of access to affordable medicines increase the possibility of 
product diversion from countries where treatment is less expensive to countries where it is more expensive. 
Pharmaceutical companies, national treatment programmes and private distributors thus implement what 
are called anti-diversion measures. Possible specific measures include product packaging that is specific 
to the treatment programme, different trade names, different colour of tablets and electronic tracking tools. 
Concerns have been raised about anti-diversion measures that have been implemented in relation to the 
new HCV medicines. Current reported practices to control the individual diversion of medicines include 
the following: 
• distribution of medicines with bar codes that include some patient information; 
• access to medicines provided on a named patient basis with proof of identification; 
• requiring proof of residence and citizenship before providing access to medication; 
• photographing the patient when he/she picks up the first bottle of medicine; 
• distribution of a limited (e.g. 2 weeks or 1 month) supply of medicine at a time, with the requirement 
that empty medicine bottles be brought or sent back in exchange for new bottle(s); 
• requiring documentation of a negative viral load result if a patient fails to return an empty bottle of 
medicine (to prove that the patient has been taking the medicine rather than having sold it). 
Preventing diversion of medicines is a legitimate concern. However, it is important that anti-diversion 
measures operate within the bounds of medical ethics. These include the following: 
• Confidentiality of patient information – access to patient-identifying information should be restricted to 
health-care providers caring for the patient. 
• Autonomy – patients have a right to make decisions about their health care, including stopping 
treatment if they so choose. 
• Privileged physician–patient interaction – treatment decisions should be made by health-care workers 
providing care to a patient. 
• Proportionality – anti-diversion measures should not put an undue burden on patients, health-care 
workers and treatment programmes.
• Non-discrimination – anti-diversion measures should not directly or indirectly restrict access to care 
for vulnerable and marginalized communities such as refugees, PWID, migrants, homeless persons or 
those with unstable living arrangements. 
Source: Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version, April 2016. 
Geneva: World Health Organization; 2016 (http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1, 
accessed 13 April 2016).
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Indonesia’s national HCV plan grew from an existing viral hepatitis plan established in 2011. In 2013, 
the Minister of Health announced that the country would provide HCV treatment in 2014, but DAAs 
were not yet on the market. Nonetheless, the national treatment guidelines include preferred and 
alternative DAA regimens (sofosbuvir/daclatasvir, sofosbuvir/ledipasvir, sofosbuvir/simeprevir and 
sofosbuvir/ribavirin). 
Application for market authorization is pending and generic versions of sofosbuvir, daclatasvir and 
sofosbuvir/ledipasvir should become available, as Indonesia is included in the licensing territories for 
these DAAs. In addition, the primary patent for daclatasvir and most of the relevant secondary patents 
have not been filed in Indonesia (see Table 3.1). 
Some challenges remain: awareness of HCV and access to diagnostics are limited, especially for 
PWID. Currently, the price for hepatitis C testing and pre-treatment assessment can be as high as 
US$ 580, triple the average monthly salary. 
Nigeria has a national hepatitis plan in place since 2013. To prepare for treatment roll-out, the country 
began drafting guidelines before DAAs were registered. The guidelines will include sofosbuvir and 
sofosbuvir/ledipasvir, daclatasvir, and paritaprevir/r/ombitasvir plus dasabuvir. The MoH is planning 
to release the guidelines as soon as DAAs become available – but the requirement for local clinical 
trials may slow down registration and access.  The WHO Patent landscape reports (26) identified no 
patents on sofosbuvir, ledipasvir, daclatasvir in Nigeria, which is also included in the respective license 
agreements, opening all possibilities for the procurement of generic DAAs (see Table 3.1). 
Romania updated its hepatitis C treatment guidelines in 2015 to include DAAs; interferon has been 
recommended since 2008. Currently, high prices have prevented widespread access to DAAs through 
the public sector. Romania is not included in the license agreements. Its situation in the heart of Europe 
with the possibility of parallel exports to other European countries will make significant price reductions 
challenging. Access to interferon-free treatment is limited to people with cirrhosis or people with pre-
cirrhosis who cannot tolerate interferon, and in liver transplant recipients with recurrent HCV. Since 
November 2015, sofosbuvir, sofosbuvir/ledipasvir, daclatasvir, simeprevir, and paritaprevir/r/ombitasvir 
plus dasabuvir have been available at district hospitals. A 28-day supply of sofosbuvir is procured at 
US$ 16 368 from the originator and a 28-day supply of daclatasvir is procured at US$ 10 289 from 
the originator company (see Table 4.1. for prices of the other DAAs in Romania, and section 3.5.3).  
4.8. Donor support and NGO partnerships
Ukraine is a middle-income country that is not included in the licensing agreements. To help ensure 
access to affordable treatment, the Alliance for Public Health, an NGO, negotiated a price reduction 
with the originator company for sofosbuvir and is providing sofosbuvir-based treatment at US$ 300 
for a 28-day supply. The Alliance began treating persons with HIV/HCV coinfection and has since 
expanded to provide HCV treatment to PWID. In less than six months, the Alliance had treated 271 
people; the cure rate among the 125 people who completed therapy was 89%. With support from the 
MoH, the project is expanding to 17 sites and plans to treat 750 people by the end of October 2016. 
In 2015, despite massive challenges in high prices and drug availability, the survey showed that 
countries are taking up the challenge to increase access to new treatments for hepatitis C. Factors 
for success included country leadership, adopting national protocols with new DAA treatment, price 
negotiation, and greater generic availability. Some of the countries such as Brazil, Egypt and Pakistan 
have emerged as pioneers in overcoming barriers and achieving accelerated access to what is now 
considered a public health priority. WHO will continue to play a strong role in policy guidance and 
responsive support to countries for enabling access to new hepatitis C drugs. 
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5. DRUG PROFILES3
These profiles include information on the registration status, pricing and production of DAA 
medicines collected by WHO through a survey of originator and generics companies. The patent 
information stems from the WHO reports on the patent situation of key products for treatment 
of hepatitis C, as updated in June 2016 (26). The objective is to increase transparency, share 
information with all partners and countries and, ultimately, to facilitate HCV treatment scale up. 
This chapter provides information on DAAs that are recommended in the 2016 WHO hepatitis C 
treatment guidelines: daclatasvir, ombitasvir/paritaprevir/r plus dasabuvir, simeprevir, sofosbuvir 
and sofosbuvir/ledipasvir (20). 
3 Unless otherwise noted, the information in this chapter comes from the WHO survey of DAA pricing, licensing, 
registration and production, and the WHO reports on the patent situation of key products for treatment of hepatitis as 
updated in June 2016 (26). 
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5.1. Daclatasvir 
General information
Therapeutic class: NS5A inhibitor
Originator company: Bristol-Myers Squibb
First approval was on 27 August 2014, by the EMA. Initially approved for use with other medicines in 
infection with HCV genotypes 1, 2, 3 and 4, the EMA on 28 January 2016 expanded the indication 
to include the use of daclatasvir/sofosbuvir ± ribavirin in people with decompensated cirrhosis, HIV/
HCV coinfection and in post-transplant patients. 
The US FDA approved daclatasvir for use with sofosbuvir in people infected with HCV genotype 3 on 
24 July 2015. On 5 February 2016, the indication was expanded to include HCV genotype 1, and 
daclatasvir/sofosbuvir ± ribavirin approved for use in people with decompensated cirrhosis, HIV/HCV 
coinfection and post-transplant patients. 
2016 WHO Guidelines 
Preferred regimen: daclatasvir used with sofosbuvir ± ribavirin for 12 or 24 weeks, in people with or 
without cirrhosis who are infected with HCV genotypes 1, 3 and 4. 
Alternative regimen: daclatasvir with sofosbuvir for 12 weeks, for people with or without cirrhosis who 
have HCV genotype 2 infection.
Dosing: 30, 60 or 90 mg, once daily.
WHO Model List of Essential Medicines. In April 2015, daclatasvir was included in the nineteenth 
edition of the WHO EML and in the thirteenth invitation to submit an expression of interest (EOI) for 
product evaluation in the WHO Prequalification Programme.
Patents. There are a number of patents covering the base compound of daclatasvir, crystalline 
forms, combinations with other DAAs and manufacturing processes. The most important 
patent is the one covering the compound WO2008021927. It has been filed widely in high-
income countries, but in relatively few LMICs. Of the countries included in the WHO reports 
on the patent situation, it has not been filed in ARIPO, Costa Rica, Ecuador, Ethiopia, Georgia, 
Indonesia, the Islamic Republic of Iran, Jordan, Malaysia, Morocco, Nigeria, OAPI, Pakistan, 
the Philippines, Ukraine, Uruguay and Viet Nam. It has been rejected in Egypt (26). Secondary 
patents can be relevant in certain cases, for example for particular combinations, but most of 
these countries should be able to locally produce daclatasvir or procure generic daclatasvir. 
Most of these countries are also included in the territory of the license agreement, which enables 
these countries to procure generic products from licensed manufacturers as well. For further 
details on the patent situation, see http://www.who.int/phi/implementation/ip_trade/ip_patent_
landscapes/en/ (26)  and Tables 3.1 and 3.2. 
Registration. Bristol-Myers Squibb, the originator company,  registered daclatasvir in Argentina, 
Brazil, Bulgaria, Colombia, Egypt, Lebanon, Mexico, Peru, the Philippines, Rwanda, Romania, 
Thailand and Ukraine. Among generic manufacturers, Hetero and Natco have obtained marketing 
authorization in India, Incepta in Bangladesh, and Pharma 5 in Morocco. 
Currently, no generic daclatasvir products have been prequalified by WHO. 
WHO Prequalification. Daclatasvir 30 mg and 60 mg from the innovator company was WHO pre-
qualified in October 2016. Currently, no generic daclatasvir products have been prequalified by WHO.
Pricing and access. Prices for a 28-day supply of daclatasvir range from US$ 21 000, the 
originator price in the USA, to US$ 61 for generic versions in India and US$ 7 in Egypt (64). 
40
Daclatasvir is relatively cheap to produce. According to recent estimates that include a 50% 
profit margin, packaging and formulation costs, a 28-day supply of daclatasvir could be sold 
for approximatively US$ 5.5.4
In November 2015, Bristol-Myers Squibb entered into a royalty-free voluntary licensing agreement for 
daclatasvir with the Medicines Patent Pool (see for further details Box 5.1). The daclatasvir voluntary 
licensing agreement enables generic manufacture of daclatasvir for sale in 112 LMICs (see Table 
3.2). Licensees have to obtain approval from the WHO Prequalification Programme, or a stringent 
drug regulatory authority. Data protection is waived, and licensees are authorized to sell outside 
the licensed territory, so as long as they do not use the technology transferred from the originator 
company, and do not infringe patents. The voluntary licensing agreement allows the licensees to 
develop FDCs with other DAAs not owned by Bristol-Myers Squibb.
So far, seven companies have signed the licensing agreement with the Medicines Patent Pool 
(Aurobindo, Cipla, Emcure, Hetero, Laurus, Natco and Zydus Cadila). Two of them, Hetero and 
Natco, are reported to be manufacturing daclatasvir and marketing it at least in India. Several other 
companies have started marketing finished formulations of daclatasvir (having purchased the API 
from Natco) in the local Indian market (Sun Pharmaceuticals Ltd, Mylan Pharmaceuticals Pvt. Ltd, 
Cadila Healthcare Ltd and Abbott India Ltd). Cipla sells the finished formulation of daclatasvir (API 
obtained from Hetero) in the local Indian market. 
Several companies are making daclatasvir available outside of the licensing agreement in countries 
where there are no patents as in Bangladesh, Egypt and Morocco. 
Known API sources include Xiamen Halo Biotechnology Ltd. (supplying Incepta), Laurus (supplying 
Natco) and Hetero Labs.
While the Medicines Patent Pool license includes more than two thirds of all middle-income countries, 
it does not include several middle-income countries with a high HCV prevalence, including Brazil (1.9 
million), China (8.9 million), Mexico (0.9 million), Thailand (0.9 million) and Ukraine (0.9 million).
4 Hill A, Simmons B, Gotham D, Fortunak J. Significant reductions in cost of generic production of sofosbuvir and 
daclatasvir for hepatitis C treatment in low- and middle-income countries. European Association for the Study of the 
Liver, International Liver Congress 2016, Barcelona, Spain, 13–17 April 2016.
Manufacturers Marketing companies/distributors Country
Local market Export
Public Private Public Private 
Incepta Pharmaceuticals Ltd.
Incepta Pharmaceuticals Ltd.
Bangladesh
N/A $141
Beximco Pharmaceuticals Ltd. N/A N/A
EVA Pharma, AUG pharma, 
AstraZeneca Pharmaceuticals, 
Marcyrl, Mash Pharma, European 
Egyptian Pharmaceutical Industries, 
Future Pharmaceutical Industries 
EVA Pharma, AUG pharma,  
AstraZeneca Pharmaceuticals, 
Marcyrl, Mash Pharma, European 
Egyptian Pharmaceutical Industries, 
Future Pharmaceutical Industries   
Egypt $7 N/A N/A N/A
Natco Pharma Ltd.
Natco Pharma Ltd
India 
$61–70 N/A $70 N/A
Abbott India Ltd $61 N/A N/A N/A
Mylan Ltd $61 
Sun Pharmaceuticals Ltd N/A N/A N/A
Zydus Heptiza (division of Cadila 
Healthcare Ltd) $61–100 N/A N/A N/A
Hetero Labs
Hetero Labs
India 
$61–80 $100 $80 $100 
Cipla Ltd N/A N/A N/A N/A
Pharma 5 Pharma 5 Morocco $120 $150 N/A N/A
Note: All prices in US dollars. Hetero and Natco prices based on the exchange rate of US$ 1=65 Indian Rupees. N/A: not available
TABLE 5.1. Prices of generic daclatasvir 60 mg, per 28-day supply, reported from Bangladesh, Egypt, India and Morocco
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5.2. Ombitasvir/paritaprevir/ritonavir ± dasabuvir 
General information
Therapeutic class: FDC of a boosted HCV protease inhibitor and an NS5A inhibitor plus a 
non-nucleoside polymerase inhibitor
Originator company: Abbvie
First approval was on 19 December 2014 by the US FDA for use in infection with genotype 1 and 
on 24 July 2015 for use in infection with genotype 4. 
2016 WHO Guidelines 
Alternative regimen: for genotype 1 infection; for subtype 1a, use with ribavirin for 12 weeks 
(no cirrhosis) or 24 weeks (compensated cirrhosis). For subtype 1b, use for 12 weeks without 
ribavirin (no cirrhosis) or with ribavirin (compensated cirrhosis). 
Alternative regimen: for genotype 4 infection (without dasabuvir); use with ribavirin for 12 weeks 
(no cirrhosis) or 24 weeks (compensated cirrhosis).
The combination is considered an alternative regimen because of safety issues (in people with 
decompensated cirrhosis, it can cause liver failure and death); drug–drug interactions with HIV 
treatment, certain hormonal contraceptives and other medicines; because it is effective against 
infection only with genotypes 1 and 4, and because it is a twice-daily regimen. 
Dosing: FDC of ombitasvir 25 mg/paritaprevir 150 mg/ritonavir 100 mg once daily ± dasabuvir 
250 mg twice daily ± ribavirin twice daily
WHO Model List of Essential Medicines. In April 2015, ombitasvir/paritaprevir/ritonavir and 
dasabuvir were included in the nineteenth edition of the WHO EML, and in the thirteenth 
invitation to submit an EOI for product evaluation in the WHO Prequalification Programme.
Patents. For all three DAAs of the combination, a number of patents are pending or granted. 
There are primary patents claiming the compounds of paritaprevir, ombitasvir and dasabuvir as 
well as patents that claim combinations of these DAAs, other combinations as well as additional 
secondary patents. The WHO patent report on ombitasvir/paritaprevir/dasabuvir lists 20 different 
patent families covering the combination. The fact that the treatment combines three different 
molecules with different patents filed for each molecule makes it more challenging for generic 
companies to circumvent patents where granted. For further details, see http://www.who.int/phi/
implementation/ip_trade/ip_patent_landscapes/en/ (26) and Table 3.1.
Registration. The originator company reported registration information. In LMICs, the dual 
combination was approved in Egypt. For the triple combination (ombitasvir/paritaprevir/
ritonavir plus dasabuvir), it  was approved in Albania, Azerbaijan, Bosnia and Herzegovina, 
Brazil, Colombia, Costa Rica, Egypt, Malaysia, Mexico, Serbia and Tunisia, and filed in Belarus, 
Dominican Republic, Ecuador, Jamaica, Panama and Thailand. Submissions are under way in 
Moldova, Morocco and South Africa. 
Pricing and access. In the United States, ombitasvir/paritaprevir/ritonavir and dasabuvir was 
launched at US$ 83 390/treatment course (although the company has offered significant 
discounts to US private payers in return for exclusivity of sales). 
The originator company of ombitasvir/paritaprevir/ritonavir plus dasabuvir has not developed 
a comprehensive medicines access programme or entered into a license agreement. It uses a 
case-by-case “access pricing” approach for Africa and other low- and lower–middle-income 
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countries. Price negotiations are under way in Algeria, Moldova, Morocco, South Africa, Tunisia 
and Ukraine. The price  in Romania is  US$ 16 145  for a 28-day supply of ombitasvir/paritaprevir/ 
ritonavir plus dasabuvir. 
The company grants compassionate use and/or early access on a case-by-case basis, based on 
therapeutic need and eligibility. Through its early access programme, the company  is currently 
providing treatment on a named patient basis in Mongolia, Tunisia, Ukraine and Viet Nam. 
In the absence of license agreements and because of patent protection around all three 
components of the treatment, and due to the complexity of the combination, there are no generic 
versions approved in any country so far. None of the generic manufacturers surveyed indicated 
that it intends to develop a generic version. 
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5.3. Simeprevir 
General information
Therapeutic class: HCV protease inhibitor
Originator company: Janssen 
First approval on 22 November 2013 (US FDA)
2016 WHO Guidelines 
Alternative regimen: simeprevir is part of an alternative regimen, recommended for use with sofosbuvir 
in genotypes 1 and 4 infection for people without cirrhosis; in people with cirrhosis with genotypes 1 
and 4 infection, either 12 weeks with ribavirin or 24 weeks without ribavirin is recommended. 
This is an alternative regimen, because of safety issues (in people with decompensated cirrhosis, it 
can cause liver failure and death); propensity for drug–drug interactions with HIV antiretrovirals and 
other medicines; the requirement for genotype 1 subgenotyping and resistance testing in genotype 
1a; and because it is effective only against infections with genotypes 1 and 4. 
Dosing: 150 mg once daily 
WHO Model List of Essential Medicines. Simeprevir is included in the nineteenth edition of the 
WHO EML (21) published in April 2015, and in the thirteenth invitation to submit an EOI for product 
evaluation in the WHO Prequalification Programme.
Patents. The WHO report on the patent situation of simeprevir comprises 12 patent families for 
simeprevir, including the primary patent claiming the base compound, which is likely to constrain 
generic competition where granted. The primary patent has been widely filed, including in ARIPO 
and OAPI, and many other LMICs. See for further details http://www.who.int/phi/implementation/
ip_trade/ip_patent_landscapes/en/ (26) and Table 3.1. 
Registration. Simeprevir is registered in a few middle-income countries, including Brazil, Bulgaria, 
Colombia, Egypt, El Salvador, Guatemala, Lebanon, Mexico, Moldova, Nicaragua, Peru, Romania, 
Thailand and Ukraine, and in one low-income country (Rwanda). The originator company  has not 
applied for WHO prequalification.
Pricing and access. Simeprevir is mainly used in high-income countries. In the US, it was launched 
at US$ 66 360 for a 12-week treatment course. Local access prices have been agreed with Brazil, 
Egypt and Indonesia. In these agreements, the prices are significantly lower than in high-income 
countries bur vary across middle-income countries from US$ 250 in Egypt, US$ 400 in Indonesia, 
US$ 866 Brazil and up to US$ 9431 in Romania for a 28-day supply of simeprevir. 
Janssen has not announced any access programme for simeprevir. The company has not entered 
into a license agreement, despite the fact that simeprevir has already been on the market for nearly 
three years. It informed WHO that it is “planning on working on a voluntary licensing agreement with 
generic manufacturers”, but that the company has “no active interest from the Medicines Patent Pool 
at this point”. It will evaluate requests for compassionate use from any country where simeprevir is 
not available. There is no generic production of simeprevir at this time, but two generic manufacturers 
(Incepta in Bangladesh and Hetero in India) reportedly plan to develop a generic version.
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5.4. Sofosbuvir 
General information
Therapeutic class: HCV nucleotide polymerase inhibitor 
Originator company: Gilead Sciences
First approval on 22 November 2013 (EMA) 
2016 WHO Guidelines 
Preferred regimen: sofosbuvir-based regimens are recommended for all HCV genotypes in people 
with or without cirrhosis. The WHO guidelines recommend the use of sofosbuvir with ribavirin, 
sofosbuvir with daclatasvir (with or without ribavirin) and the FDC of sofosbuvir/ledipasvir with or 
without ribavirin. 
Alternative regimen: sofosbuvir plus simeprevir is an alternative regimen for infection with HCV 
genotypes 1 and 4, and sofosbuvir is included in an alternative regimen for infection with HCV 
genotypes 5 and 6, with pegylated interferon and ribavirin.
WHO Model List of Essential Medicines. Sofosbuvir is included in the nineteenth edition of the WHO 
EML (21) published in April 2015 and was included in the WHO prequalification programme. 
Patents. The WHO report on the patent situation of sofosbuvir comprises 14 different patent families 
out of the large number of patents filed and covering different aspects of sofosbuvir. The patents 
cover the compound, the prodrug, crystalline forms, formulations and combinations. The primary 
patents that claim the compound and the prodrug have not been filed in certain countries or regions 
(see http://www.who.int/phi/implementation/ip_trade/ip_patent_landscapes/en/ (26) and Table 3.1). 
Secondary patents have been filed more widely and thus require screening as to what extent they 
are relevant to local production or importation of generic versions. NGOs and competitors have filed 
a number of patent oppositions in different jurisdictions, and different patent applications have been 
rejected in ARIPO, Egypt, Ukraine and other countries. Most of these countries are also included in 
the territory of the license agreement. See for further details http://www.who.int/phi/implementation/
ip_trade/ip_patent_landscapes/en/ (26) and Table 3.1. 
Registration. Information about the registration status of sofosbuvir is available online (77, 95). The 
innovator company announced that it endeavours to register its hepatitis products in all countries 
included in its access programme (101 countries) using the royalties of the license agreements to 
finance this activity. 
Sofosbuvir has been registered in many high-income countries, including Argentina, Chile, Uruguay 
and Venezuela, as well as in a number of LMICs: Bolivia, Brazil, Bulgaria, Dominican Republic, 
Egypt, El Salvador, Georgia, India, Indonesia, Mexico, Mongolia, Pakistan, Peru, the Philippines, 
Romania, Thailand, Ukraine, and one low-income country, Rwanda. Registration for sofosbuvir is 
pending in 11 other LMICs, eight of which are in the licensed territory.  
WHO Prequalification. None of the generic formulations produced by the different companies 
has been prequalified or approved by a stringent regulatory authority. Seven generic products and 
four API manufacturers have entered the official phase of WHO prequalification; see section 3.3 
for more details. 
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TABLE 5.2. Status of registration of generic sofosbuvir 400 mg, reported by generic companies
Company Approved Submitted Dossier in preparation 
Hetero Algeria, Bangladesh, Democratic 
Republic of the Congo, Egypt, India, 
Nepal
Kenya, Benin, Myanmar,  
Viet Nam   
19, including Ukraine
Natco Kyrgyzstan, Nepal 36 countries
Strides 20 countries including Egypt,  
Nigeria, South Africa
Pharco Azerbaijan, Egypt, Kyrgyzstan  
and Ukraine
Cadila India
Pharma 5 Côte d’Ivoire, Guinea, Morocco
Incepta 24 countries 
Richmond Argentina
Getz Pharma Pakistan
Pricing and access. In the USA, sofosbuvir was launched in 2013 at US$ 1000 per pill, or US$ 28 
000 for a 28-day supply. Since then, the price has declined through negotiations with medicines 
distributors and public sector agencies such as the U.S. Veterans Administration. The high price 
has led public and private payers in high-income countries to institute non-evidence-based access 
restrictions – including for those with a history of current or past injection drug use. Prices in high-
income countries remain high and put serious pressure on health systems (see Chapter 3). 
In countries that are not included in the voluntary license agreement and in high-income countries, 
the innovator company, Gilead Sciences, negotiates prices on a country-by-country basis without 
disclosing the negotiated price publicly. In Brazil, the price of sofosbuvir was negotiated at US$ 2292 
for a 28-day supply; after a joint negotiation between the company and the Mercosur countries and 
their Associate States, all of them were offered the same price as Brazil (except Argentina, as shown 
in Table 4.1) (83). In Romania, sofosbuvir costs US$ 16 368 for a 28-day supply.   
The voluntary licensing agreement of the innovator company covers 101 LMICs. It includes the 
sofosbuvir/ledipasvir FDC and the sofosbuvir/velpatasvir FDC. The innovator company  has signed 
agreements with 11 generics manufacturers in India, two generics manufacturers in Egypt and 
one manufacturer in Pakistan. The latter agreements allow them to import or manufacture and sell 
sofosbuvir in their national markets; see Chapter 3 for more detail.
Licensees cannot export their finished product or APIs to countries where patents have been awarded 
or are pending. Countries where no patents are in force can, however, buy sofosbuvir or sofosbuvir/
ledipasvir from manufacturers that have not signed the license agreement with Gilead Sciences. 
The 101 countries in the territory include all low-income and many but not all middle-income 
countries. The agreement does not include several middle-income countries with a high HCV 
prevalence, including Brazil (1.9 million), China (8.9 million), Mexico (0.9 million), Thailand (0.9 
million) and Ukraine (0.9 million) (see Chapter 3 for further details on the license agreement). 
These countries can buy from the 11 Indian licensees or directly from Gilead Sciences, which 
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TABLE 5.3. Prices of generic sofosbuvir 400 mg, per 28-day supply, reported from Bangladesh Egypt, India (64), 
Morocco and Pakistan
offers sofosbuvir for US$ 300 for a 28-day supply to all countries included in the agreement 
under its differential pricing scheme. Reported prices of sofosbuvir in the local Indian market 
vary from US$ 169 to US$ 338. Generics producers offer sofosbuvir at much lower prices, 
down to US$ 51 per month in Egypt’s public sector and US$ 15 in Pakistan. A few companies 
quoted prices for exporting sofosbuvir: Cipla US$ 233/28-day supply; Hetero US$ 250–300/28-
day supply; Natco US$ 199/28-day supply; Pharco US$ 60 and US$ 76/28-day supply (for the 
public and private sectors, respectively), and Strides Shasun for US$ 300/28-day supply (Tables 
5.3 and 5.4). Table 5.5 gives a list of companies that produce the API of sofosbuvir.
Anti-diversion measures. To access the reduced prices offered by Gilead Sciences and its licensees, 
countries must implement Gilead Sciences’ anti-diversion measures; so far, this has been documented 
in Egypt, Georgia, Pakistan, Romania and Rwanda. It is important that such programmes do not 
compromise patient autonomy, confidentiality, the patient–medical provider relationship, and do not 
logistically complicate procurement and delay treatment scale up (see Chapter 4, Box 4.2). 
Manufacturers 
Marketing companies/  
Distributors
Country
Local market Export
Public Private Public Private 
Incepta  
Pharmaceuticals Ltd.
Incepta Pharmaceuticals Ltd. Bangladesh N/A $197 N/A N/A
Pharco* Pharco* Egypt $51 $70 $70–85 N/A
Natco  Pharma Ltd.
Natco Pharma Ltd
India 
N/A $149 N/A $199
Emcure Pharmaceuticals Ltd N/A $154 N/A N/A
Mylan Ltd N/A $163 N/A N/A
Strides Shansun N/A $108 N/A $300
Zydus Heptiza (division  
of Cadila Healthcare Ltd)
N/A $185 N/A N/A
Hetero Labs
Hetero Labs N/A $185 N/A $250–$300
Abbott India Ltd N/A $192 N/A N/A
Biocon N/A $215 N/A N/A
Cipla Ltd N/A $169 N/A $233
Dr Reddy’s N/A $215 N/A N/A
Ranbaxy N/A $154 N/A N/A
Sun Pharmaceuticals Ltd N/A $180 N/A N/A
Pharma 5 Pharma 5 Morocco N/A $300 N/A N/A
Getz Pharma Getz Pharma Pakistan N/A $15–42 N/A N/A
*26 other manufacturers or distributors are currently producing or marketing generic sofosbuvir in Egypt.  
Note: All prices in US dollars. Indian prices based on the exchange rate of US$ 1=65 Indian Rupees (64)
N/A: not available
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TABLE 5.5. Companies that produce the active pharmaceutical ingredient for sofosbuvir 400 mg 
Company Type of license Country
Companies producing with a Gilead VL 
Laurus International India
Sequent International India
Hetero International India
Companies producing without a Gilead VL 
CAD Middle East Pharmaceutical industries LLC None Saudi Arabia
Pharco None Egypt
Xiamen Halogenetics Biotechnology Ltd None China
TABLE 5.4. Companies that produce or market sofosbuvir 400 mg
Distributor Manufacturer of the finished formulation Type of license with Gilead Sciences Country of origin
Companies with a VL from Gilead 
Hetero1 Hetero International India
Biocon Hetero International India
Cipla Hetero International India
Sun Pharma Hetero International India
Natco1 Natco International India
Cadila Natco International India
Mylan Natco International India
Strides Shasun Natco International India
Companies with a national VL from Gilead
Pharmed  
Healthcare
Gilead In-country Egypt
Magic Pharma Gilead In-country Egypt
Ferozsons Gilead In-country Pakistan
Companies outside of the Gilead VL 
Richmond Richmond N/A Argentina
Incepta Incepta N/A Bangladesh
Beximco Beximco N/A Bangladesh
Pharco Pharco N/A Egypt
Abbott India Ltd. Hetero N/A India
Dr Reddy’s Hetero N/A India
Emcure Natco N/A India
Pharma 5 Pharma 5 N/A Morocco
Getz Pharma Getz Pharma N/A Pakistan
Note: 26 other manufacturers or distributors are currently producing or marketing generic sofosbuvir in Egypt.  
1 Hetero and Natco market sofosbuvir under their own name, but also sell finished formulation to other companies.
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5.5. Sofosbuvir/ledipasvir 
General information
Therapeutic class: FDC of a nucleotide polymerase inhibitor and an NS5A inhibitor
Originator company: Gilead Sciences
First approval on 10 October 2014 (US FDA)
2016 WHO Guidelines 
Preferred regimen: sofosbuvir/ledipasvir is recommended for infection with HCV genotypes 1, 4, 5 
and 6 in people with or without cirrhosis. The WHO guidelines recommend the use of sofosbuvir/
ledipasvir with or without ribavirin for 12 or 24 weeks. 
WHO Model List of Essential Medicines. Sofosbuvir/ledipasvir is included in the nineteenth edition 
of WHO EML (21) published in April 2015, and in the thirteenth invitation to submit an EOI for 
product evaluation in the WHO Prequalification Programme. 
Patents. The WHO Report on the patent situation of ledipasvir (26) lists seven different patent families 
for ledipasvir with the primary patent covering the compound WO2010132601 being the most 
important one for generic competition. This patent has been widely filed, including in the two regional 
African patent offices, ARIPO and OPAI. Table 3.1 provides an overview of the patent situation in 
the countries included in the WHO patent reports. Most of the countries where the primary patent 
has not been filed or granted are included in the territory of the license agreement, for example, the 
Philippines, but there are also some countries outside the license agreement, for example, Georgia, 
Iran, Jordan and Malaysia. Secondary patents can be relevant, in particular, where they cover relevant 
combinations of DAAs (see, for example, Patents 5 and 6 in WHO Patent situation of key products 
for treatment of hepatitis C, updated June 2016 – ledipasvir and the report on sofosbuvir (26) and 
Tables 3.1 and 3.2). 
Registration. Information about the registration status of sofosbuvir/ledipasvir  of the originator 
company is available online (77). The company announced that it endeavours to register its hepatitis 
products in all countries included in its access programme (101 countries) using the royalties of the 
license agreements to finance this activity. Sofosbuvir/ledipasvir has been registered in eight LMICs: 
Egypt, Ethiopia, Georgia, Mexico, Mongolia, Morocco, Rwanda, Tunisia and Uruguay.  Registration for 
sofosbuvir/ledipasvir is pending in 12 other LMICs, nine of which are in the licensed territory.  
WHO Prequalification. For the time being, none of the generic formulations available from different 
companies has undergone approval by a stringent regulatory authority or prequalification. Several 
generics companies plan to apply for WHO prequalification for their versions.
Pricing and access. Sofosbuvir/ledipasvir is covered by the same voluntary licensing agreement as 
sofosbuvir (see Chapter 3 for details). 
The 101 countries included can purchase generic sofosbuvir/ledipasvir from the 11 Indian 
licensees or buy sofosbuvir/ledipasvir for US$ 400 per 28-day supply from the originator company 
under its differential pricing scheme. Several generics companies reported offering the combination 
at prices ranging from US$ 250 to US$ 450 per 28-day supply, either producing or marketing 
sofosbuvir/ledipasvir (Tables 5.6 and 5.7). Table 5.8 gives the companies that produce the APIs for 
sofosbuvir/ledipasvir.
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TABLE 5.6. Price of generic sofosbuvir/ledipasvir 400 mg/90 mg in selected countries
Country (generics suppliers) Sector
Price range, US$,  
per 28-day supply
India (Cadila, Hetero, Natco, Sun Pharma)
Public 250–400
Private 450
Bangladesh (Incepta) Private 353
TABLE 5.8. Companies that produce the active pharmaceutical ingredients for sofosbuvir/ledipasvir 400 mg/90 mg 
Company Type of license Country
Companies producing under the Gilead license
Laurus International India
Hetero International India
Companies producing without a Gilead license
CAD Middle East Pharmaceutical industries LLC None Saudi Arabia
Pharco None Egypt
Xiamen Halogenetics Biotechnology Ltd. None China
TABLE 5.7. Companies that produce or market sofosbuvir/ledipasvir 400 mg/90 mg
Distributor
Manufacturer of the 
finished formulation 
Type of license 
agreement 
Country of origin
Companies selling or producing finished formulations of sofosbuvir/ledipasvir with a license from Gilead Sciences  
(101 countries/territories)
Hetero1 Hetero International India
Cipla N/A International India
Sun Pharma Hetero International India
Natco1 Natco International India
Cadila Hetero International India
Mylan N/A International India
Companies selling or producing finished formulations with a national license
None reported
Companies selling or producing finished formulations of sofosbuvir/ledipasvir without a Gilead license
Incepta Incepta None Bangladesh
Beximco Beximco None Bangladesh
Pharmed Health Care, Future Pharmaceutical 
Industries, Marcyrl co., Organo Pharma, 
Averroes Pharmaceuticals  
N/A None Egypt
1 Hetero and Natco market sofosbuvir/ledipasvir under their own names, but also sell finished formulation to other companies. 
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